JP2006526575A - Enhanced bioavailability of nutrients, drugs, and other bioactive substances by laser resonance homogenization or modification of molecular or crystalline forms - Google Patents

Abstract

A method for improving the bioavailability of a bioactive material includes subjecting the bioactive material to laser radiation. Laser radiation alters a bioactive substance, thereby altering the response to that substance in the body. The method allows for the reduction of inflammation associated with autoimmune diseases, alteration of reaction by-products in the body, increased homogenization and flattening of molecular shape, and improved methylation. Improved methylation can be used to reduce blood levels of homocysteine and reduce anxiety, depression, paranoia, hostility, somatization (perception of physical distress) and obsessive-compulsive symptoms. Enhanced nitric oxide production from modified L-arginine can be used to reduce systolic and diastolic blood pressure, to reduce total and LDL cholesterol levels, and to improve the total to HDL cholesterol ratio. Increasing the penetration depth of sparse constructive nodes of laser radiation can increase the scope of photodynamic therapy applications and the wide range of in vitro and in vivo variations in molecular shape and activity. Laser acoustic resonance can be conveniently used to increase crystal homogeneity or to produce new or preferred crystal forms.

Description

BACKGROUND The present invention relates to novel food amino acids and nutritional products, as well as fortified pharmaceuticals and methods for their production. More particularly, the present invention relates to products and methods such that the product has an advantageously modified bioactive reaction profile, and the method of manufacturing the product is by a specially amplitude-modulated and constructed laser light exposure process. . These processes alter reaction characteristics by altering the binding structure and shape of the molecules in the compound, resulting in enhancement of certain suitable biological responses, at least after an initial period after ingestion or administration. In other cases, a less favorable reaction can be suppressed, so that the product can be more precisely tailored to the needs and provide the desired treatment or nutritional effect.

  The body and special organs of the body use nutrients in a variety of complex ways. These biological processes often occur in enzymes that are moderately moderated. The efficiency of a given nutrient or compound depends on the relative ease with which it can be taken up by the body in the desired form. For purposes of this disclosure, this ease of incorporation will be referred to as “bioavailability”. Thus, it will be understood that when referring to increased bioavailability, depending on the context of the discussion, it may relate to the amount of compound utilized by the body, or the rate or efficiency at which the compound is utilized.

  Furthermore, improved bioavailability may be an improvement in the absorption mode of a compound. In other words, the absorption of nutrients or drugs with reduced irritation or adverse effects is an improvement in bioavailability even if the actual amount of compound absorbed is not increased.

  From Strachan's PCT / GB00 / 03280, constructing sparse nodes of constructive interference of electromagnetic (EM) waves generated as fast as sub-femtoseconds, organic and other molecular media It is known that it can selectively stimulate specific molecular resonances much more efficiently than normal laser EM stimulation, overcoming many limitations of the scattering path through.

  Normally, laser EM stimulation is subject to abrupt alteration to non-specific thermal effects when passing through a scattering medium. In contrast, EM radiation with sparse constructive node beams maintains polarization and magnetic field structure sufficiently stable, so that the polar and hydrophobic regions of the molecule can absorb laser energy from these sparse constructive nodes. It absorbs differentially and is affected by structural binding energy, mainly due to the acoustic resonance of the molecule. This will change the shape of the molecule and consequently the chemical reactivity.

  Sparse constructive nodes are generated and modulated through an optical device such as that described in Strachan EP 865618 A1. Specifically, the laser beam passes through the first diffraction grating, the refractive element, and the second diffraction grating such that the beam is substantially canceled.

  The refractive element produces cancellation over a few percent of the chromatic dispersion of the laser source, rather than cancellation at one critical wavelength. This means that a composite Fresnel / Fraunhofer band is generated, defined by high and low beat frequencies as a function of aperture.

  Thus, a relatively sparse zone of constructive interference will occur in the selected direction from the aperture while high and low frequencies pass through the cancellation element. Depending on the partial change of the laser wavelength or the relative amplitude of the laser wavelength, the position of these nodes moves rapidly. In fact, a continuous beam is converted into a string of pulses of very short duration, typically sub-femtoseconds, by a simple means of relatively small low frequency amplitude modulation.

  Strachan (PCT / GB00 / 03280) also describes the use of an array of constructive nodal beams to continuously cause and facilitate protein folding steps that are very similar to chaperonin-like effects. Yes. Furthermore, amino acid structures that may have a heterogeneous form in the dry state can be homogenized to a more self-consistent form and the biological reactivity of the structure can be selectively altered.

  In particular, homogenization can make metabolic utilization significantly more efficient. This is because the enzyme mild reaction is consequently made easier by reducing the range of crystal forms. This is especially seen when the resulting form is generally more polar and increases the production of the desired product relatively faster than usual, thereby reducing non-specific degradation of the substrate.

  Strachan also describes the ability to favor the production of the desired “handed” structure in chiral compounds (and epimers by logical extension). The method either modifies the beam with the resonance of the structure to either enhance the production of the desired rotation or reduce the production of the less desirable rotation. This last effect can be further promoted by applying a rotational component to the polarization state of the beam.

Summary of the Invention Strachan teaches that the structure of various compositions can be modified, but focuses primarily on cell adhesion, integrins and apoptosis. However, the present invention is very advantageous for the modification of amino acids, phytonutrients, nutrients and food substances, drugs, and other bioactive substances, regardless of the method of administration by Strachan. It has been found that the bioavailability of a substance can be changed and / or the body's response to that substance can be changed.

  At a basic level, the present invention involves a method that utilizes the technique taught by Strachan for molecular stimulation. In particular, when a beam of light passes through a bioactive substance, resonance passes in a manner that causes the molecular structure of the molecule to change. This may be molecular folding, promotion or suppression of certain “handedness” of a stereoisomer molecule, or simply a change in the molecular size of the molecule. However, by selectively controlling the molecule, significant changes can be made in bioavailability and / or physiological response to the molecule.

  Inherent line variations of gas lasers without etalon or other line narrowing devices are appropriate to provide the partial frequency shift necessary for crossing sparse constructive nodes through the mixture. The polarization plane of the laser defines the main axis of crystal formation or strain for the dry state. Note that circularly polarized lasers tend to favor crystallization of one stereoisomer over the other. Further control of the final molecular form can be provided by modulating the laser amplitude at a frequency that resonates with a given bond or linking group in the molecule or crystal.

  In the absence of specific amplitude modulation, the modulation that occurs across the constructive node due to the line instability of the laser tends to impart thermal energy to the carbon-hydrogen and carbon-oxygen and hydrogen-oxygen bonds, while spreading. And planar and cyclic carbon bonds remain low energy. This will tend to “dry” the crystal form in that it tends to reduce the water content in the molecule.

  For the most part, as a result of this effect, stray hydrogen bonds tend to grow at least temporarily in the molecule. Dried molecules (even in solution) naturally result in crystalline forms that are less constrained by hydrophobic nodes. In the absence of this force, the laser stimulation and thermal vibration of the outer bond is favored by the flat molecular shape. Thus, amino acid compounds and isomers typically tend to crystallize somewhat more or less randomly from various seed crystals in solution depending on the distribution of bound water under laser stimulation, but the overwhelming number of crystals Formation will be the flattest form of the molecule. Therefore, the entire “mixture” of random molecular configurations tends to be very homogeneous.

  While this process may seem best applied during the initial crystallization, in practice it is not necessary. This is because the laser can stimulate the water bonds directly to effectively “evaporate” the bound water in the dry state and also change the bond formation in solution form. In addition to the water-bonding effect, asymmetric heating of the molecule combined with the field force from the EM wave itself will induce a flatter state in all cases where the modulation frequency is below 3 MHz and above 100 KHz. Let's go.

  Although specific molecular forms can be derived through the use of specific modulation frequencies and cross-node velocities, this patent primarily deals with the bulk effect of laser acoustic resonance and its application to manipulation of nutritional supplements and drug physiological effects. .

  In this regard, those skilled in the art of desired physiological and pharmacological effects will determine which of the group of amino acids or bioactive substances is to be metabolized preferentially or temporally prior to the other components of the mixture. In view of this, the metabolic absorption of a compound can be adjusted by the disclosed methods accordingly.

  The present invention relates to certain compounds that are processed according to the disclosed methods with the simple intention of increasing or altering the metabolic rate of the overall mixture. This produces the measured crystallographic effect described. The resulting physiological effects can be inferred from the results of the following bioassays and clinical trials.

  The efficiency of laser stimulation is improved if the compound is maintained at a neutral pH and exposed at a background temperature of 25-30 ° C. The average power of laser stimulation is very low, less than raising the temperature of the bulk substrate more than 1 degree per mole per second, otherwise purely random thermal effects dominate the laser resonance and field effects Is extremely important.

  The sparse constructive node of the optical system taught by Strachan is an island of constructive interference that moves fast in the background of photons, which is highly advanced through photostructural destructive interference at the center frequency of the laser wavelength band. Self-cancelled. The beat frequency that occurs as the difference between the highest and lowest frequencies of the laser wavelength band produces a constructive node that is placed very accurately in space. The next photon packet reaches the same space in resonance with the traversal of the preceding photon packet. The resulting array of resonant constructive nodes behaves as if it were a series of ultrashort pulses separated spatially and temporally by a very self-interfering wave intervening medium. The duration of these effective pulse nodes can be as short as sub-femtoseconds in traversing the molecular structure.

  An impulse or “bang” to each molecule from a sparse constructive node is defined as a retransmission from the molecule stimulated to ring by photon absorption or acoustic resonance from the node. Photon absorption or retransmission is described in mathematical terms as Dirac (ie, impulses that act as essentially infinite high and infinite narrow spikes). In order for any structure to ring at the resonant frequency, it must be stimulated at a frequency equal to or higher than its natural frequency, i.e., satisfied by any photon absorption or emission.

  The passage of a molecule from a constructive node with a high photon absorption potential into an intervening space of a much larger destructive node with a very low photon absorption capability is likely to cause the molecule to emit photons during the intervening time. That is, it is likely to drop the electron orbit of one or more of its atoms. Ideally, the constructive node is provided strictly at this frequency, since the molecule will respond to both absorption and emission of photons in response to acoustic vibrations into the molecular backbone.

  However, although this is ideal, the presentation of any constructive node that is substantially lower in frequency than the main skeletal resonance, but still faster than the decay time of the molecular resonance, delivers a flattening or stretching effect to the molecule. This is suitable for continuous wave laser stimulation. The delivery of the ideal frequency is best, but there appears to be interference between the constructive node and the substrate-bound acoustic energy even a little above this frequency. It may reduce irritation to the continuous wave laser effect, or basic thermal heating.

  As an alternative to delivering the exact resonant frequency of the backbone of a given molecule, it often delivers a low-modulation-frequency pulse train “bang and ring” effect that is sufficient to cause rapid node movement and is completely It may be desirable to avoid potential frequency overshoots (which can be broken down into purely random thermal effects) when trying to deliver a tuned wave.

  For a typical homogenization process, the reagent inhomogeneity may be sufficient to counteract high-wave delivery of pure waves, so it is lower than the molecular backbone resonance frequency but less than the molecular decay time. Delivery of a pulse train frequency that is still fast can often lead to better results than attempting to match the resonance frequency of the molecular backbone.

  In special cases where more specific molecular effects are desired, the first step is to tune the constructive node frequency with that of skeletal or other specific intramolecular resonances following general molecular homogenization. Could be.

  The frequency of the sparse constructive node uses a wide or narrow band Strachan optical interference plate, uses a main laser with a wide or narrow emission linewidth, adjusts the aperture or angle of the interference plate, and a high or low frequency laser Or can be tuned by modulating the main laser beam by electronic amplitude modulation or by passing the beam through an acousto-optic crystal modulation system.

  High frequency modulation can be achieved by broadband interference plates, the use of lasers with wide wavelength emission line widths, the use of high frequency lasers, or high frequency main beam modulation prior to traversing the Strachan optical interferometer.

  The transition of a sparse constructive node that passes through a given point is defined as the complex interaction of adding different phases of beat frequency and modulation of beat frequency. This is due to the change in the relative amplitude and position of the upper and lower limits of the laser emission line width across the interference band of the Strachan optical device and the center frequency of the laser.

  The modulation of the laser can be very gradual even if the constructive interfering node moves very fast through a fixed point in space. Even without laser modulation, the upper and lower beat frequencies can still produce moving, rather than stationary, constructive waves. If the transition frequency of the constructive node can be any non-zero when the modulation frequency is zero, then the node transition frequency is generally higher than the modulation frequency.

  Several frequencies are always involved. That is, the non-cancelled laser frequencies above the interference cancellation frequency and the frequencies below the canceled frequency, their beat frequencies as sums and differences, and the spatial separation of the constructive node versus the cross-phase velocity. The last depends on the aperture and frequency involved.

There is also an absorption “pulse” of the transition of the electron shell when an atom absorbs or emits a photon. This can be regarded as infinite compared to other frequencies.
A sparse constructive node beam differs significantly from a conventional continuous wave laser in its interaction with the molecular structure. When molecules absorb photons from a conventional continuous wave laser, the stimulated atoms tend to remain excited with electrons in the excitation shell. This is because atoms are always collided by photons unless there is a weakening node. Atoms in the excited state will reflect more photons. The atoms cannot absorb any more photons from the continuous beam, so they are not excited anymore and cannot effectively emit photons. This is because as soon as the electron shell tries to fall to low energy, another photon collides from the beam, and the molecular structure is not acoustically excited.

  However, in the case of a sparse constructive node beam, atoms absorb photons, and molecules resonate slightly because they redistribute the kinetic energy of absorption. Photon absorption sends a pulse wave along the skeleton to the other end of the molecule, which is then reflected back to the starting point. Thus, the processes of absorption, movement down the skeleton to the opposite end, and reflection to the starting point are inherently prone to occur at the natural frequency of the skeleton, which is determined by the shape, size, and composition of the molecule. If the next weakening node lasts long enough, the acoustic signal of kinetic energy will reflect down the skeleton and will emit photons. Again, the kinetic energy of the emission will be distributed along the skeleton.

  In the case of an ideally tuned sparse constructive node beam, the motion sound wave hits the edge of the molecule and reflects off to the starting point, so a new constructive node arrives at the molecule and again excites ground state atoms into the high shell. To do. In the case of this resonance using the tuned sparse constructive node described, the arriving photon “shock” is tuned to the previous photon absorption and emission shock ringing. Thus, the total kinetic energy of the molecule is now twice that expected when stimulated with a normal continuous wave laser.

  The process repeats as described above, and depending on the decay loss of the molecule (depending on the structure of the bond), the kinetic energy will be generated by these two to thousands of factors. Thus, the kinetic energy or temperature of a molecule is substantially higher with respect to its local environment.

  If the constructive nodes are too close, the described resonance accumulation will be hampered by not having sufficient relaxation time for photon re-emission. Similarly, molecule-to-molecule binding of acoustic energy through the medium in which the molecule is present (water in the case of a solution, solid if the molecule is in powder form) will tend to interfere with the pure resonance described above. Too much or too close acoustic coupling tends to have the same effect as sparse nodes being too close, so the result is that the molecule cannot absorb and emit photons at the ideal resonant frequency, and the net The ability to amplify kinetic energy decreases.

  There is an important difference between the sparse constructive node effect and a conventional continuous wave laser with respect to the energy transferred to the stimulated molecule. When a molecule is exposed to a continuous wave of light of a given wavelength, all possible atoms will absorb photons and have excited electrons. Hydrogen atoms are temporarily destroyed; once this happens, the thermal effect causes the bulk molecule to oscillate with large amplitudes, but only with random forces on the individual molecules.

  Conversely, in the case of sparse constructive node irradiation, individual molecules are rarely saturated with all possible photon absorption. Rather, there is time to absorb and emit photons, which tends to be so at the skeletal resonance frequency. Thus, the energy exchanged with the skeleton is higher in the sparse node mode than in the continuous wave laser mode, and the molecule is excited to a highly polarized electromagnetic field state that is not possible in the highly scattering continuous wave mode.

  Excitation of molecules by laser stimulation of sparse constructive nodes occurs by photon absorption and emission. This absorption and emission can be viewed as an infinite frequency impulse, just as the impact of the bell clapper is infinite with respect to the bell ringing frequency. While molecules are excited by their absorption and emission, molecules are also under stress from electromagnetic and magnetic fields. This stress is generally very large for the stimulated molecule.

  For example, L-arginine and betaine molecules are only a few nanometers long, while the laser wavelength for stimulation experiments is 670 nanometers long. The effect can be regarded as similar to tapping a sheet of iron scrap placed on a magnet. If you don't hit the sheet, the iron scrap sticks to the sheet. When you hit the sheet, the iron scrap moves freely for a short time. In the absence of a magnetic field, they would simply be randomly distributed, but in the presence of a magnetic field, they align along the magnetic field lines.

Similarly, for sparse constructive node irradiation, sheet hitting is represented by photon absorption and emission. On the other hand, the EM field at the wavelength of the laser frequency represents the entire field lines.
Through this process, the molecule undergoes a very long wavelength field effect of the EM wave of a given polarization (the molecule tends to be attracted according to the magnetic field). At the same time, one or more atoms in the molecule absorb individual photons from the node. This ensures that the molecules tend to ring at their natural frequency and tend to align with the magnetic field.

  If a specific effect beyond the flattening and stretching effect of low frequency mere “shock and ring” is desired, a specific binding resonance frequency may be given for a given molecule. This will be a very high frequency, not a general homogenization effect caused by low frequencies and sparse nodes, but a very specific change to the molecule. These changes range from breaking specific molecular bonds (possibly for the purpose of immediately incorporating a cleaved fragment into another molecule) to preferentially linking particular ends of molecules in the polymerization process.

  The estimated dose of laser irradiation to achieve a general molecular homogenization effect is estimated to be as short as 3 seconds per mole per milliwatt of applied laser energy under ideal particle exposure conditions for betaine molecules. . If the particle size and dispersion are smaller or the particles are suspended in the air, this process could be made more efficient. Using the betaine treatment molar ratio, an approximate fastest rate of homogenization effect is obtained at a dose of 30 seconds / kg / mW.

  For large molecules, the processing time per mole and milliwatt is increased, but this increases roughly in proportion to the molecular weight, so the fastest effective processing time per kilogram will remain approximately the same. Even if the treatment time is longer than necessary, the effect is further enhanced as long as the applied radiation is generally less or significantly less than would increase the bulk temperature of the treated species by 1 mole and more than 1 ° C. per second. It is neither easy nor purely reducing the thermal effect.

  For practical purposes, to increase the maximum homogenization effect trend, the treatment dose is usually about 1 min per milliwatt per sparse constructive node laser irradiation. 03-. It is in the range of 05 kilograms.

  When comparing and contrasting sparse constructive node laser EM irradiation with everyday continuous wave lasers, several essential differences appear. As described in Strachan's PCT / GB00 / 03280, the visible wavelength penetration depth of a conventional laser EM through a highly scattering medium such as human skin is typically even at the most transmitted wavelengths. It is less than 5 mm. In contrast, the pulse train of sparse constructive nodes can have 60 mm effective coherent transmission through the skin, and even greater transmission in other tissues, thanks to much less scattering.

  In the case of a combination therapy such as photodynamic therapy (PDT) in which the action of a photosensitive compound such as a benzoporphyrin derivative is combined with the application of photons to cause a photo-oxidation reaction and remove pathogenic tissues, Applying laser irradiation can greatly expand the current (technical) reach of this combination therapy.

  For practical purposes, e.g. in the treatment of malignant tumors, photodynamic therapy is applied to endoscopically visible lesions of the respiratory or gastrointestinal tract, or laser EM transmitted locally or fibroscopes of the skin. Limited to other locations that are directly accessible by signal. The penetration of effective coherent signals to deeper depths should broaden the range of malignant lesions and other PDT sensitive conditions where this generally effective and well tolerated therapy is available for treatment.

  Conventional lasers usually produce constructive and destructive nodes in the same ratio, so the overall output energy ratio is small. Generally much less than 1% of the output energy. Even with the modulated beam of a conventional laser EM, there is not enough relaxation time before the next photon entry to allow efficient emission per cycle of absorbed photons. On the other hand, in the sparse constructive node beam, the destructive node is highly dominant and highly constructed in light emission from the optical device.

  When atoms absorb photons from a conventional laser beam, the atoms become highly reflective of additional photons until they emit the absorbed photons. Atoms tend to remain excited and reflected because there are not enough destructive nodes to allow conduction of sufficient energy from the atom before the next packet arrives for absorption.

  In contrast, in the case of laser EM irradiation of a sparse constructive node, each atom is excited in resonance with the molecular skeleton. The intervening destructive node crossing allows the decay to the ground state by the emission of photons. Thus, the atom is ready to absorb the next photon from the constructive node when it arrives, and the resonance effect is sustained and enhanced.

  High level surface reflection due to molecular photon absorption from conventional laser irradiation causes strong photon scattering at the irradiated surface. All light is scattered and ejected at the beginning of the entrance of the beam through the absorbing medium. Only the surface has flare, but then scatters and interferes with potential resonance effects.

  On the other hand, in the case of a sparse constructive node beam, the constructive node is rare and the weakening node is dominant. The spacing between constructive nodes allows intramolecular resonance and intermolecular tuning. Unlike bright continuous wave beams, the sparse constructive node effect spreads through the medium, so the effect is less scattered, allowing deeper transmission and greater degree of molecular resonance stimulation.

  Pulsed conventional lasers with short pulse duration may have overcome some limitations of continuous wave lasers with respect to resonant stimulation, but there are no dominant (many) destructive nodes in the pulse wave Therefore, it still tends to cause a high degree of surface scattering. Very short constructive nodes with a relaxed nodal relaxation phase tend to enhance the performance of constructive nodal beams that are sparser than ordinary pulsed laser beams with respect to acoustic resonance and coherent depth of transmission.

  The performance of conventional pulsed lasers in stimulating molecular resonances would be expected to improve if the pulse itself could be built into a sparse constructive node by passing the pulsed beam through Strachan's interferometric optics. .

  Conventional continuous wave laser irradiation is likely to strike a molecule more than once per resonance cycle of the irradiated molecule. On the other hand, in the laser irradiation of a sparse constructive node, the possibility of another photon hitting an atom during the excitation period is low, but the possibility of once per cycle is high.

  Consider several bells in a line for analogy. Scattering of scattered photons in a continuous wave laser beam crushes the initial bell resonance. In contrast, sparse constructive node irradiation stimulates the resonance ringing of the first bell, which in turn stimulates the other bells to start ringing and moves the resonance signal deep into the irradiation medium. In this way, sparse constructive nodes can stimulate intramolecular and intermolecular resonances. In a sparse constructive node, it is possible to construct a cycle of molecular resonance that increases the kinetic energy of the molecule by adjusting the photon's arrival potential to the intended molecule.

  Continuous wave laser irradiation causes an abrupt increase in thermal energy conducted randomly from the center of stimulation at the absorbing surface. In contrast, sparse constructive nodes deliver less energy but deliver this energy to a very specific location through resonance. The build energy possessed per molecule can be many times greater than the energy delivered through conventional continuous wave laser stimulation, increasing the reactivity of the processing molecules.

  Continuous wave laser irradiation excites molecules, but then there must be a valley. This is similar to kicking a swing continuously, delivering an impact that is out of phase with the natural frequency of the swing period. Sparse constructive nodes deliver less energy, but deliver energy in phase with the natural frequency of the molecule being stimulated. The kinetic energy stored in the molecular skeleton structure stretches and flattens the molecule.

  Moreover, this tends to remove bound water from the molecules, resulting in a dry structure even in molecules already in dry powder form. Hydrogen bonds can be rearranged to change solubility factors. There is also the possibility of changing the free energy of the chemical bonds reconstructed in this way.

  In general, stretched and flattened shapes stimulated by sparse constructive node laser irradiation tend to be highly homogeneous from molecule to molecule (between molecules). Molecules homogenized in this way tend to have a lower total energy composition and higher electric and magnetic field moments than molecules not homogenized in this process.

  Homogeneity, flattened and elongated shape, and high electric and magnetic field moments favor the efficient binding of substrate and enzyme or ligand and receptor site. In particular, it is advantageous for binding the next reactant molecule to the enzyme (when the next reactant is highly similar in shape to the reactant just released from the enzyme).

  Conventional continuous wave laser irradiation is unlikely to maintain resonance, excites everything and delivers photons at the wrong time. It is therefore inefficient to change the shape of the molecule in a consistent manner. In contrast, laser irradiation of sparse constructive nodes is inherently efficient in stimulating the natural frequencies of molecules and homogenizing their shapes.

  Chemical reactions and especially enzyme-catalyzed reactions are highly shape dependent. The relatively random effects on molecular shape that occur with conventional laser irradiation can hardly help increase the efficiency of chemical reactions other than speeding up only by thermal heating (with the exception of wavelength-specific photochemical reactions). In contrast, laser irradiation of sparse constructive nodes can provide very great control over chemical reactions. This can be done through the homogenization of the substrate or through the specific heating of the binding that is desired to be more active in the reaction process.

  Stimulation by sparse constructive nodes is particularly advantageous in reactions where heating damages one reagent but the others remain intact. Sparse constructive node irradiation can be used to heat the temperature tolerant substrate while leaving the temperature sensitive reactant intact.

  In the case of chemical reactions, particularly chemical reactions that are gently advanced by enzymes, the homogenization process can increase the chemical potential or potential difference that drives the chemical reaction. The chemical potential depends on the intrinsic properties of the substrate and product molecules and their concentrations. When the reaction process A + B = C + D is reversible, the direction and rate of the reaction depends on the nature of A, B, C, and D and the effective amount of each. The more A and B are added, the more C and D are formed. The reverse is also true. Also, as soon as C and D are formed, the reaction proceeds to the right.

  The homogeneity of the reactant is equivalent to an increase in concentration. Because the reaction surface of the cell can be more regular and thus more compact, and the enzyme can be the same molecule as the molecule just released (even if it is slightly different in size). Because it combines fairly quickly.

  Considering the chemical potential defined above for an enzyme mild reaction, increasing the homogeneity of one or more reactants increases the effective concentration of the reactants and the energy of the first step of binding of the reactants to the enzyme. This is equivalent to a decrease. This is because an enzyme that fits one molecule requires substantially no energy to fit the next if the shape of the substrate is the same, and in the case of a highly heterogeneously crystallized reactant. This is because it is not necessary to produce a wide range of enzymes to moderate the predetermined reaction. The energy potential of the reaction increases as the effective concentration of reactants increases.

  Some molecules will change the free energy of certain bonds because of the overall shape change of the molecule. Depending on the desired product, this can be both an aid and an obstacle to the production of a given product. However, increased binding energy and dimensional similarity from molecule to molecule always facilitates product production in enzyme mild reactions. Although the effect on each interaction may be small, the overall effect can be substantial.

  The rate at which a reactant can be supplied to an enzyme or receptor is directly proportional to the molecular self-similarity of the reactant or receptor ligand. Thus, a given amount of a reactant or receptor ligand can produce more product or stimulate a stronger receptor effect, the greater the mutual self-similarity of the reactant molecules. Molecules irradiated at sparse constructive nodes are generally very similar to each other with respect to shape and size, water distribution and location, and relatively high electric and magnetic field moments for the molecular species.

  One particular advantage of the present invention is that the homogenizing action of L-arginine on a dry powder can be transformed into a differential effect in vitro after the dry powder is dissolved into solution. is there. Thus, treatment of the dry powder causes structural changes in the molecules that change bioavailability and / or physiological response to the substance. This in turn substantially alters the availability of the substance by the body, particularly the mammalian body. The substance is stable enough to maintain a molecular stimulating effect that produces an enhanced biological effect even after the substance is dissolved in solution. Furthermore, similar enhancements can be produced using the method on solutions containing substances.

  In accordance with another aspect of the invention, the method is used to alter the physiological production of nitric oxide from the amino acid L-arginine. For a given molar concentration of L-arginine, nitric oxide production from macrophages in vitro increases or decreases statistically significantly, depending on the applied laser resonance. Thus, the present invention can be used to increase or decrease unwanted by-products associated with nutrients, drugs, or other bioactive substances of the body.

  In accordance with another aspect of the present invention, the method relates to increasing the ability of L-arginine to amplify the widespread physiological benefits of reported arginine-induced nitric oxide (ADNO). These physiological benefits include ADNO's blood pressure lowering effect (with minimal physiological side effects); bronchodilation and improved lung function test results; mediating long-term potentiation in nerve tissue and thereby promoting memory function; hemoglobin Improving tissue oxygen supply through related mechanisms; reducing LDL and total cholesterol levels and LDL oxidation; promoting growth hormone release and its widespread anti-aging benefits; improving microvascular blood flow and tissue perfusion; Such as the production of nitric oxide “bombs” for direct antimicrobial and antitumor effects, increased natural killer cell activity, and enhanced cytokine production (eg, tumor necrosis factor-α) However, it is not limited to these.

  Furthermore, the ADNO effect mediated through increased cyclic guanosine monophosphate (cyclic-GMP) production is also enhanced. For example, the effects of ADNO via cyclic GMP on male sexual performance enhancement and possibly female vaginal lubrication, and increased genital susceptibility in both sexes.

  According to yet another aspect of the present invention, reducing the ability of L-arginine to produce ADNO preserves the nutritional benefits of L-arginine, while L-arginine can occur under special circumstances in sensitive individuals It has been found that the risk of adverse effects of supplementation can be reduced. These situations include humans with herpes simplex virus infection (L-arginine supplementation can increase the risk of onset) and inflammatory conditions (L-arginine supplementation can exacerbate non-specific inflammatory symptoms) However, it is not limited to these. In particular, a reduction in the risk of developing herpes simplex can be obtained by a combination of the use of low potency L-arginine and the addition of at least 1 g of amino acid L-lysine per day.

  An additional aspect of the invention relates to the ability to alter hydrophobic and hydrophilic interactions by laser resonance. This is observed through X-ray crystallography. In particular, the method can be used to develop new forms of L-arginine hydrochloride and other molecular structures, both dry and in solution.

  For example, using the disclosed method, the crystal structure of L-arginine hydrochloride grown without or with laser resonance stimulation was compared. L-arginine hydrochloride was dissolved in deionized water and then crystallized by slow evaporation at room temperature with and without laser stimulation. Typical characteristics of L-arginine hydrochloride monohydrate reported in the literature that the control L-arginine hydrochloride has one water molecule per L-arginine hydrochloride molecule in the crystal lattice in the crystal structure solution. It turns out that it has. Laser treated L-arginine hydrochloride showed a significantly different crystal structure. That is, L-arginine hydrochloride did not contain water in the crystal lattice, and exhibited different unit cell characteristics and high uniformity of nitrogen-containing side chains.

  Laser-treated L-arginine hydrochloride with sparse constructive nodes showed the expected effect of high levels of homogenization and reduction of bound water in the molecular structure. This result suggests the ability to change a wide range of molecular structures in the intended manner, either in the dry state or in solution.

In accordance with one aspect of the present invention, Strachan's method (or other molecular modification method) can be used to alter the immunological effect of a full spectrum of amino acid blends.
In accordance with this aspect of the invention, an amino acid or blend of amino acids that are hyperimmune stimulants is laser treated. The laser alters the structure of the amino acids to reduce immune stimulation to baseline levels without amino acids. In other words, altering the amino acid structure reduces the negative immune response to the amino acid. Such modified nutrition would be highly desirable for humans with poor nitrogen balance and immune overactivity, such as autoimmune diseases, food allergies, and other inflammatory conditions such as inflammatory bowel disease . Thus, in accordance with this aspect of the present invention, a basic, easily absorbed and assimilated nutrient pathway is provided that does not further exacerbate the underlying inflammatory condition.

  In accordance with yet another aspect of the present invention, an improved method of administration of food nucleic acid elements and food nucleotide precursors is disclosed. In a presently preferred embodiment of one aspect of the present invention, a method is disclosed that does not require parenteral administration, but provides better delivery of nucleic acid elements to tissues than oral ingestion.

  Metabolic uptake studies indicate that orally administered purines and pyrimidines undergo significant metabolic degradation by both intestinal bacteria and intestinal epithelium. The uptake rate of orally administered pyrimidine is approximately 5% in the intestinal mucosa and only 3% in the liver. Orally ingested purines are more extensively oxidized, resulting in less than 1% purine nucleosides being incorporated into the liver nucleic acid pool.

  Studies with radiolabeled purines have shown that intravenous injection results in significantly higher uptake rates in certain metabolically active tissues compared to ingestion. IV: Oral uptake rates are as high as 29-51: 1 in the pituitary, thymus, salivary gland, thyroid, adrenal gland, and lymphoid tissues.

  Recent evidence indicates that although the body can produce nucleobases from amino acids and other precursors, the ability of some tissues to synthesize it is necessary for optimal tissue maintenance, repair, and regeneration. not filled. This is especially true for lymphoid tissue, especially when under stress conditions. Numerous studies have shown significant immunological benefits of supplementing nucleic acid elements, particularly for improved cellular immunity. Animal studies have shown significant improvements in outcome for systemic bacterial and fungal infections and malignant tumors. Human studies have shown significant improvements in cellular immunity and enhanced intestinal growth, maturation, and repair.

  To overcome the limitations of oral intake, the present disclosure presents delivery of nucleic acid elements by oral spray formulations or rectal or vaginal suppositories as a preferred embodiment of one aspect of the present invention. Absorption studies suggest that nutrients applied to the oral mucosa can achieve direct systemic absorption of up to 90% and also overcome the limitations of hepatic first-pass metabolism. These elements can include one or more of the following forms. Laser treated DNA and RNA nucleobases, nucleosides and deoxynucleosides, and nucleotide and deoxynucleotide monophosphates, diphosphates, and triphosphates. Laser treatment of nucleotides and deoxynucleotides is capable of, at least temporarily, producing higher energy, higher biologically active, high energy phosphate groups.

  This formulation contains one or more laser homogenized amino acids, in particular amino acids known to be precursors of in vivo nucleobase synthesis, namely glycine, L-glutamine, L-serine, and L-aspartic acid. It may be. The formulation may also contain one or more laser-treated vitamins, minerals, trace elements, and other nutrient cofactors that support nucleotide metabolism. This laser-irradiated formulation for enhancing nucleic acid metabolism can also be provided through intravenous or other parenteral injection routes such as subcutaneous or intramuscular injection. Laser treated nucleic acid elements may be expected to have improved absorption over untreated, but significant degradation by the intestinal mucosa remains the same.

  In accordance with yet another aspect of the invention, the method is also used to create a homogenized form of trimethylglycine (TMG). TMG, also known as betaine, is a methyl group donor that participates in many basic chemical pathways in the body.

  TMG is derived from the simplest amino acid glycine and has three methyl groups replacing the three hydrogen atoms of the amino group. X-ray crystallography comparing the control and laser-treated betaine hydrochloride shows the effects of molecular homogenization and planarization and elongation of molecules as expected.

  Homogenization that creates greater self-similarity in molecular shape is indicated by a marked reduction in crystal defects in the laser treated sample compared to the control sample (both samples were crystallized by slow evaporation at room temperature). Though). The number of defects in the control crystal is to be predicted because the shape of the untreated compound is extensive and difficult to fit uniformly in the crystal lattice.

  In contrast, consistent planarization and elongated shapes from molecule to molecule allow for faster incorporation into a uniform crystal lattice. X-ray crystallographic analysis shows a clear three-dimensional form of control and treated betaine hydrochloride, which is consistent with the expected shape change.

  The laser treated sample in particular shows the planarization and elongation of the carbon-nitrogen bond of the aminomethyl group, to a lesser extent, the planarization of the carbon-hydrogen bond of the methyl group and the carbon-oxygen bond of the carboxyl group and It also suggests elongation. This flattened shape tends to have high field energy and reduced binding energy, favoring low energy enzyme binding and high enzyme reactivity.

Current evidence shows that this activated state creates reactive methyl groups that promote various biological processes in the body, providing countless benefits to the body.
For example, betaine is a betaine that converts the blood concentration of homocysteine, a substance that is involved in a number of negative physiological states, to transfer the methyl group from betaine to homocysteine and convert homocysteine to the amino acid methionine. It has been found that it can be reduced through homocysteine methyltransferase enzyme.

  By providing activated betaine in combination with nutrients that act as cofactors in the transmethylation pathway in the body, significant homocysteine reduction can be achieved. It limits the risk of heart attacks, strokes, dementia, pre-eclampsia and certain malignancies, especially malignant tumors of epithelial origin, such as cervical cancer, colon cancer, and possibly bronchogenic neoplasms. The

Activated betaines and cofactors can also be used to reduce the scales of anxiety, depression, hostility, paranoia, somatization (aches and pains of the body), and obsessive-compulsive symptoms.
In light of the present disclosure, it will be appreciated that various chemical entities can be modified in accordance with the principles of the present invention. In particular, any organic molecule that is twisted or deformed in shape through a chemical synthesis, purification, or drying process is homogenized into a more self-similar and bioavailable shape.

  This process tends to be relatively inefficient for small molecules with low rotational freedom or planar ring molecules, but like L-arginine with long unsaturated mobile side chains that can take many ground-state shapes. These molecules are very suitable for homogenization and shape reshaping by this process.

The enhanced amino acids and other substances described in this invention can be provided as a dry powder or as a solution through several routes of administration. These include oral sprays, mucous membranes, oral intake, enteral feeding tubes, parenteral by various routes, and local routes.
Detailed Description of the Invention The above and other objects, features and advantages of the present invention will become apparent from a consideration of the following detailed description provided in conjunction with the accompanying drawings.

  Various aspects of the invention are described below to enable those skilled in the art to make and use the invention. It should be understood that the following description is merely illustrative of the principles of various aspects of the invention and should not be taken as a limitation on the scope of the appended claims. It should also be understood that each aspect may not achieve the respective objectives of the present invention, but provides one or more advantages over the prior art.

Example 1
Production of highly homogenous simvastatin with increased crystallinity by application of laser acoustic resonance USP standard simvastatin, 21 mg each of two samples, was used in this study. Each sample was dissolved in 200 mg of 100% ethanol and placed in a 10 × 35 mm polystyrene petri dish. Sim1A was prepared as an untreated control, Sim1B was prepared for processing by modulated acoustically sparsely coupled nodes by laser acoustic resonance, and differences in crystallinity were evaluated using X-ray powder diffraction.

  Both samples were crystallized by slow evaporation at room temperature. Since Sim1A served as a control, no additional processing method was applied. Sim1B was treated with a 670 nm diode laser whose 4.7 mW primary power was phase conjugated through an optical element to a power level of 2.35 mW. The beam was modulated at 10 MHz and passed through the center of the liquid meniscus of the solution until sample 2 was completely crystallized. The two samples were then sent to a reference laboratory for X-ray powder diffraction (XRPD) testing.

  FIG. 1A shows the XRPD pattern of Sim1A, a control simvastatin standard. FIG. 1B shows an XRPD pattern of Sim1B that has been subjected to laser acoustic resonance processing. The corresponding peak in FIG. 1B is ˜70% larger than in FIG. 1A. The sharp degradation of Sim1B and the significantly increased reflection amplitude indicate the high crystallinity of Sim1B.

  Based on thermodynamic considerations, increased crystallinity is associated with increased crystal form stability. For storage purposes of drugs or other compounds, the higher crystalline form tends to have a significantly longer shelf life because it is easier to maintain its form and properties for a longer period of time.

  Perhaps more importantly, the risk of conversion to a different crystalline form during storage can be reduced. This is because such a conversion can greatly change the effect of the compound in the body. In particular, in the case of metastable crystal forms that are not already in the lowest free energy form, an increase in crystallinity of the metastable form is highly undesirable to a more stable form that is usually avoided due to low solubility and low bioavailability. Can reduce the risk of conversion. Increasing the likelihood of being able to maintain a metastable form in a predictable manner can provide such compounds that must be provided in this form with significant advantages of sufficient solubility and bioavailability with clinical benefit.

Example 2
Preparation of partially amorphous simvastatin by application of laser acoustic resonance Two samples of simvastatin, a US Pharmacopoeia (USP) standard, 21 mg each were used as an extension of the test described in Example 1. Each sample was dissolved in 200 mg of 100% ethanol and placed in a 10 × 35 mm polystyrene petri dish. Sim2A and Sim2B were prepared for processing by modulated acoustically sparsely strengthened nodes by laser acoustic resonance, and differences in crystallinity were evaluated using X-ray powder diffraction.

  Both samples were crystallized by slow evaporation at room temperature. Sim2A was treated with a 458 nm excited argon gas laser with a 2.1 mW primary power phase-conjugated through an optical element to a power level of 1.05 mW. The beam was modulated at 6.4 MHz and passed through the center of the liquid meniscus of the solution until sample 2A was completely crystallized. Sim2B was treated with a Quantel Nd-YAG pulsed laser (467 nm, 5 nanosecond average pulse amplitude 2-5 mJ / pulse, 12 pulses per second). The optic was adjusted for maximum cancellation and the beam was passed through the center of the solution liquid meniscus until sample 2B was completely crystallized. The two samples were then sent to a reference laboratory for X-ray powder diffraction (XRPD) testing.

  FIG. 2A shows the XRPD pattern of Sim2A, and FIG. 2B shows the XRPD pattern of Sim2B. The Sim2A XRPD pattern exhibits a relatively low intensity reflection, and the Sim2A XRPD pattern exhibits a very low intensity reflection. Since the low-intensity reflection can be attributed to the amorphous content, the pattern of Sim2B suggests a higher amorphous content than Sim2A.

  Sim2A and Sim2B solidified in appearance to a glassy state, and only slight crystal growth was seen compared to the conservatively grown crystal formation of Sim1A and the highly grown crystal formation of Sim1B. The degree of glassy appearance observed with Sim2A and Sim2B was consistent with the degree of amorphous content suggested by XRPD.

  Amorphous materials generally have significantly higher free energy than crystalline materials of the same material. Because of their high energy state, they tend to have higher solubility and faster dissolution rates than their low energy crystalline counterparts. In many cases, the amorphous form of the pharmaceutical compound is selected for clinical use, as the crystalline form has low solubility and low bioavailability limiting its clinical value. Even in the case of simvastatin, the absorption rate and bioavailability can be increased by adding a considerable amorphous content to the composition, so that a large medicinal effect can be obtained at a low dose. If low doses prove to be sufficient for the desired clinical outcome, the potential for adverse effects may also be reduced.

  In contrast to extreme conditions far from equilibrium, often required for the production of amorphous forms, laser acoustic resonance can achieve this formation at room temperature and pressure without dramatic changes in pH. Avoidance of extreme conditions can reduce the degradation of compounds that can occur under more aggressive conditions, improve the yield of the product, and possibly result in a more stable amorphous form.

  The application of laser acoustic resonance with modulated sparse constructive nodes can provide a means to ensure that compounds that are otherwise difficult to produce in amorphous form are produced in amorphous form. This can rescue compounds that appear to be clinically useful but cannot achieve sufficient solubility to be effective in an amorphous form. For other compounds, the production of a stable amorphous content can increase bioavailability to the extent that it increases clinical efficacy, reduces dose requirements, or reduces the risk of adverse effects.

Example 3
Increasing Arginine-Induced Nitric Oxide Production by Laser Treatment Use of laser modification of a compound enhances the ability to modify not only the compound itself, but also the byproducts created by the body's use of the modified compound.

  For example, 4 samples of L-arginine (Arg), each 20 g, were weighed 3 for laser treatment and 1 for untreated controls. Arg # 1 was treated with a Quantel Nd-YAG pulsed laser (532 nm, 5 nanosecond average pulse amplitude 2-5 mJ / pulse, 12 pulses per second). The optical apparatus was adjusted for maximum cancellation and the sample was processed for 30 seconds. Arg # 2 was treated with a 458 nm pumped argon gas laser with a primary output of 16.5 mW adjusted through an optical device to a power level of 5.06 mW. Arg # 3 was processed with a 670 nm diode laser with a primary power of 4.85 mW adjusted to an output level of 2.94 mW through an optical element. Arg # 4 was an untreated control sample.

  The following bioassay was performed at Paracelsian, Ithaca, New York, an external independent laboratory. Each arginine sample was added to 12 wells of mouse macrophages to a concentration of 120 mcg / ml. This is an estimated serum concentration after a 70 kg human has ingested 6 g of arginine, which is the concentration observed in a number of clinical trials in connection with a wide range of physiological benefits. 1 ng / ml LPS was added to each well and the cells were incubated for 24 hours. Nitrite concentration in the supernatant of each well was measured as a relative measurement of nitric oxide production 24 hours after the start of treatment.

  The results are arranged in order of relative nitrite production, from largest to smallest. The first column was determined from the Arg number (#), the second column was determined from the optical density average plus or minus standard deviation (measurement of nitrite concentration) measured at 540 nm, and the third column was determined from the optical density. Relative production of nitrite (expressed in micrograms per ml). The last column shows the results of a student's one-sided T-test comparing maximum production Arg # 3 with the other samples.

  Laser modulation applied to Arg # 3 resulted in the production of a statistically significant more nitric oxide byproduct in this sample than the control untreated Arg # 4. The laser modulation applied to Arg # 1 and Arg # 2 produced significantly less nitric oxide byproduct than the control untreated Arg # 4 and much more than laser activated Arg # 3 Resulted in the production of nitric oxide byproduct, which was statistically significantly less.

  Since the maximal effect of L-arginine donation on nitric oxide production in vitro and in vivo is likely to be seen within the first 30-60 minutes of feeding, a 24-hour equilibration study is a laser treatment for the control form of L-arginine. It is very important to note that the maximum magnitude of the difference in form of nitric oxide production may be substantially underestimated.

  This example demonstrates the ability to change the production of the intended metabolic byproduct significantly upwards or downwards depending on the laser stimulus applied. The experiment was performed at an energy level that was small enough not to cause ionization or significant thermal decomposition. A change in molecular shape that does not change the effect after the dried material is in solution is very likely to moderate the enzyme-substrate compatibility and the intended reaction rate.

Example 4
Homogenization, elongation, and dehydration of L-arginine hydrochloride by laser resonance stimulation 135 mg L-arginine hydrochloride was weighed into each of two 10 × 35 mm polystyrene petri dishes. Each sample. Dissolved in 50 g of deionized water. The control sample crystallized by slow evaporation at room temperature over 24 hours. The average room temperature was approximately 26 ° C. The average ambient humidity was approximately 33%.

  The treated sample was crystallized under the same conditions by applying the pulse modulation energy of 532 nm described in Arg # 1 of Example 2 above. The beam was passed through the center of the meniscus of the solution in the container.

  Control and treated sample crystals were selected for further testing. All of the selected crystals are approximately one side according to the latest standards in the art. It had a dimension of 5 mm or less. The crystal structure was analyzed using a SMART X-ray diffraction analyzer.

  There was a very significant difference between the control and laser treated crystals. FIG. 3A shows a somewhat bulky and irregular crystal habit from the front and side of the control sample. On the other hand, FIG. 3B shows a more homogeneous and cylindrical habit of laser-treated L-arginine hydrochloride on the corresponding drawing. The control L-arginine hydrochloride was found to have the typical unit cell properties of monohydrate crystals reported in the literature. In contrast, the laser treated crystals were found to have significantly different unit cells without water in the crystal lattice, indicating conversion from monohydrate to anhydride crystals. This is particularly important because the crystallization was made from water at room temperature. As shown in FIG. 3C, and according to the predicted effect of skeletal resonance stimulation by sparse constructive nodes, a high level of homogenization of the stretched L-arginine structure is seen in the lattice.

  The process described in the present invention has the potential to be applied to a wide range of molecular forms to alter the relative strength of hydrophilic and hydrophobic interactions. Pretreatment of the dried material can up-regulate or down-regulate a particular reaction process in the intended direction. Crystals grown from solution using this process may have new and desired properties. This process can also be applied in solution to change reaction rates and product ratios. The sparse constructive node of laser EM waves has a deep penetration depth into the medium, which can extend this process to a wide range of industrial, in vitro, and in vivo applications.

Example 5
Reduction of inflammatory cytokine production by laser treatment of a full spectrum blend of amino acids A mixture of amino acids was prepared as follows. The following free amino acid dry powders were weighed and mixed in the following proportions. L-cysteine 3.4 g, L-taurine 6.8 g, L-threonine 27.0 g, glycine 368.4 g, L-glutamate base 67.6 g, L-glutamine 67.6 g, L-lysine monohydrochloride 67.6 g L-arginine 60.8 g, L-aspartic acid 13.6 g, L-ornithine monohydrochloride 12.2 g, L-histidine 13.6 g, L-leucine 60.8 g, L-valine 33.8 g, L-methionine 33.8 g, DL-phenylalanine 129.0 g, L-isoleucine 40.6 g, L-alanine 16.8 g, L-proline 13.6 g, L-serine 33.8 g, and L-citrulline 10.2 g.

  20 g each of this mixture was used for control and laser treated samples. Sample 1 is a control, Sample 2 is treated with a 670 nm diode laser with a 4.85 mW primary output adjusted to a power level of 2.94 mW through an optical element, and Sample 3 outputs a 16.5 mW primary output through an optical device. Processing was performed with a 458 nm excitation argon gas laser adjusted to a level of 5.06 mW. Samples 2 and 3 each had a laser treatment time of 30 seconds.

  The following bioassay was performed at Paracelsian, Ithaca, New York, an independent external laboratory. Standardized echinacea samples alone or with 20 mg / ml samples 1, 2, or 3 were incubated for 24 hours in triplate well tissue medium of mouse macrophages after echinacea stimulation, then in 3 ELISA wells Tumor necrosis factor-α (TNF-α) production was assayed. Positive and negative controls using 1 ng / ml lipopolysaccharide (LPS) were similarly assayed.

One skilled in the art will appreciate that the use of mouse macrophages stimulates the body's immune response. The addition of the herbal echinacea provides a response similar to that of the immune system being stimulated. The TNF-α reading is a good marker of the degree of inflammation. Thus, substances that cause a significant increase in TNF-α in macrophages are the human body, especially autoimmune diseases such as inflammatory bowel disease, and other physiological such as systemic lupus erythematosus, rheumatoid arthritis and food allergies. It can be expected to cause significant inflammation in the body in question.
The results were as follows.

  Echinacea positive controls were compared to Echinacea + sample 1, 2, or 3 results using Student's two-tailed T-test. Addition of sample 1 added to TNF-α with p <. It resulted in a very significant increase of 0001. The relative increase in TNF-α production was not so great after the addition of sample 2, but nevertheless p <. 03 was statistically significant. Addition of sample 3 did not significantly increase TNF-α production (p = .31). Thus, laser treatment of sample 3 reduced the strong increase in TNF-α production observed in control sample 1 and returned to echinacea-only baseline levels.

  In other words, the negative control indicates the immune system of a normal person. The addition of echinacea enhanced the immune response. The addition of lipopolysaccharide (LPS) simulates maximal immune stimulation (as a basis for evaluation).

  Addition of sample 1 of unmodified amino acid showed a significant increase in TNF-α production. Thus, humans with autoimmune diseases or other inflammatory processes are expected to develop significant inflammation as a result of amino acid intake.

  Unlike sample 1, sample 2 and sample 3 were modified as indicated above. The sample not only created a strong potential for inflammation as shown by Sample 1, but also had a very small increase in TNF-α. In fact, Sample 3 showed virtually no increase in inflammation of the Echinacea positive control.

  If you are familiar with nutrition, you will find that there are many who cannot tolerate certain nutrients necessary for good health. The aforementioned amino acids are major examples. By laser processing various amino acids, the bioavailability of amino acids can be greatly increased. Clearly, if a person with an autoimmune disease or other inflammatory condition does not react negatively to amino acids, a significant amount can be incorporated into the person's diet without the risk of unwanted side effects. .

  One skilled in the art will appreciate that inflammation is not always bad. Often an enhanced immune response is desired. For example, increased inflammatory / immunological activity can be used to combat tumors or other undesirable conditions. By changing the laser treatment of a chemical, the chemical can be changed to increase rather than reduce the immune response. From laser-treated L-arginine, as already shown through the case of increased nitric oxide production of macrophages compared to untreated controls.

Example 6
Improvement of brain coherence using laser homogenized amino acids versus untreated amino acids An electroencephalogram (EEG) is a diagnostic test in which recording electrodes are placed throughout the brain to measure the pattern of electrical activity in the brain. Quantitative EEG, or brain map, is a detailed test that measures the output of the EEG in frequency bands delta, theta, alpha, and beta, expressed in microvolts. In addition, brain maps measure coherence. That is, a measurement as to whether the phase of the electroencephalogram from one region to another is in a relationship consistent with healthy or impaired brain function.

  The standard condition for quantitative EEG is to avoid caffeine and other irritants in the morning after a good night's sleep. A cap with a conductive electrode is placed over the entire scalp so that the electrode is localized in the brain area of a specific area. The measurement is performed for 20 to 30 minutes with the eyes closed and the subject resting in the supine position. Once the baseline and post-intervention measurements have been made, the same protocol is performed with the cap intact to ensure the reliability of localization from measurement to measurement. Resting with eyes closed tends to cause a significant enhancement of the alpha wave band of 8-12 cycles per second, making this wave band particularly important for research interpretation. The quantitative EEG device used in the following tests measured output and coherence data at 19 different locations throughout the brain.

  The test formulation consisted of a blend of amino acids intended to increase mental energy, concentration and alertness. The two most important amino acids for increased brain energy and arousal are L-phenylalanine and L-tyrosine. This is because they are precursors of the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine. In the standard chemical pathway, L-phenylalanine is hydroxylated to L-tyrosine and then itself hydroxylated to form L-dopa. The enzyme L-dopa decarboxylase then converts L-dopa to dopamine; then differential hydroxylation of dopamine yields either the other major catecholamine neurotransmitters norepinephrine or epinephrine. These are neurotransmitters that can have deep stimulating effects on the central nervous system and systemically.

  The test formulation was composed of the following components expressed in weight%: L-tyrosine 6.6%, L-phenylalanine 3.3%, DL-phenylalanine 2.2%, glycine 4.4%, L-arginine. 7.7%, L-ornithine 7.7%, L-lysine 3.3%, L-taurine 6.6%, L-glutathione 9.9%, L-glutamic acid 5.5%, L-glutamine 4. 4%, L-methionine 4.4%, L-cystine 7.7%, L-cysteine 3.3%, L-alanine 5.5%, L-threonine 2.2%, L-valine 6.6% L-isoleucine 4.4%, L-leucine 1.1%, L-histidine 2.2%, and L-aspartic acid 1.1%. 750 mg test preparation per capsule was placed in a clear gelatin capsule. Control untreated capsules were not changed further. The laser-treated capsule was irradiated with an excitation argon laser beam of 458 nm like arginine # 3 of Example 1. The treatment capsules passed through the beam while rotating slowly for 1 minute per capsule.

  Subjects were two young adult Caucasian women with no medical problems and no history of brain injury or neurological disease. They were chosen as subjects representing the physiological response of the brains of young healthy individuals. As expected, baseline quantitative EEG showed alpha wave predominance as expected when the eyes were closed and rested. After taking a baseline reading, each subject received 2 capsules of untreated test formulation (total 1.5 g per subject). After 30 minutes for absorption and assimilation of the formulation, quantitative EEG measurements were repeated. After measurement of the untreated test formulation, the subject then took 2 capsules of the laser treated formulation (total 1.5 g per subject). After allowing 30 minutes for absorption and assimilation of the treated formulation, the quantitative EEG measurement was repeated again.

  The table below shows the mean and standard deviation (SD) values of the alpha band output at baseline, after untreated amino acids, and after treated amino acids.

Using a general linear model repeated measures analysis of variance, the effects of laser-excited amino acid formulations on brain output enhancement were analyzed by comparing baseline, untreated formulation intake, and laser treated formulation intake. Multivariate tests show a marked increase in brain output above baseline, and Wilks' Lambda =. 219, F (2,36) = 64.128, p ≦. 0001. According to the paired two-tailed t-test, a significant increase in brain output above baseline was seen after ingestion of untreated and laser-treated amino acids, both comparisons p <. It was statistically significant at 0001. Furthermore, the laser treated amino acid formulation is t (37) = − 2.349, p =. At 024, brain output was significantly increased over the untreated formulation.

  Moreover, the use of laser-treated formulations also showed significantly better coherence results than using untreated amino acid formulations. One of the two subjects had the adverse effect of significantly reducing alpha EEG coherence after ingestion of untreated amino acids, but improved better than baseline after ingestion of laser treated amino acids. FIG. 4A shows a baseline coherence test of the subject, and one electroencephalogram coherence abnormality is observed in the left occipital region of the brain. After ingestion of the untreated amino acid formulation, FIG. 4B shows the expansion of coherence abnormalities. Eleven areas of abnormalities have progressed from one abnormality in the baseline, and a bilateral intensity coherence abnormality from front to back and a coherence abnormality region between hemispheres are also shown. After laser-treated amino acid ingestion, FIG. 4C shows complete resolution of all coherence abnormalities. The use of laser-treated amino acids not only demonstrated the ability to significantly increase brain output over untreated amino acids, but also demonstrated the ability to reverse the adverse effects of abnormal EEG coherence that occurred with the use of untreated amino acids. In particular, phenolic neurotransmitter precursor shape heterogeneity and skeletal twist may tend to have inconsistent receptor effects and suboptimal neurophysiological responses.

  In the case of commercially available L-tyrosine, the heating and dehydration processes that the molecule undergoes, especially the process of withdrawing water molecules from the structure, can lead to twisting of the backbone chain phenolic ring or other deformation of the molecular shape. In the case of untreated L-tyrosine, such a shape can contribute to the occurrence of coherence abnormalities because it cannot provide optimal receptor fit for the catecholamine neurotransmitter metabolite. Homogenization of the shape of laser-treated L-phenylalanine and L-tyrosine may be a key factor that promotes the recovery of normal brain coherence that may occur through improved receptor adaptation of neurotransmitters (increased at the same time) Brain energy is also sustained).

  Similarly, L-dopa is subject to heat and dehydration stress during commercial manufacture. These stresses also cause molecular deformation of the phenol ring alignment on the skeleton. Widely used as a treatment for Parkinson's disease, L-Dopa provides a substrate that increases deficient dopamine levels in specific brain regions of such conditions, particularly the substantia nigra and other striatal nuclei. To do. Since L-dopa is usually administered with carbidopa, a dopa decarboxylase inhibitor outside the brain, the concentration of L-dopa that crosses the blood brain barrier is high.

  L-dopa can help relieve movement disorders in Parkinson's disease, but its use is often accompanied by side effects such as nausea and agitation. In many cases, doses need to be increased as the efficacy diminishes, which also tends to increase side effects and can cause dose limitations. Homogenizing L-dopa using laser resonance results in a shape that more consistently promotes the intended clinical effect while reducing the side effect profile. A pre-determined amount of laser-treated L-dopa could provide equal or better clinical benefit, reduce the tendency for adverse effects, and delay the need for dose escalation. The initial protocol used for laser treatment of L-dopa will follow the practices used to process the amino acid formulations described above, but will be scaled up to meet commercial production levels and supplied with a high volume of powder. The

Example 7
Laser irradiation of sparse constructive nodes in accordance with the present invention in the quality of crystal formation with planarized and elongated carbon-nitrogen, carbon-hydrogen, and carbon-oxygen bonds in laser-treated betaine hydrochloride compared to untreated betaine hydrochloride Was used to resonate the molecules of betaine hydrochloride to a uniform flattened and elongated shape. The homogenization effect is observed at a significantly improved level of crystal formation of laser treated betaine hydrochloride compared to the untreated control. X-ray crystallography of laser-treated betaine hydrochloride shows the expected flattening and elongation of bonds in the treated molecule compared to the control untreated molecule.

  Samples of the control and treated betaine hydrochloride shown in FIGS. 5A, 5B, 5C, 5D, and 5E were prepared in this manner by dissolving 0.6 g betaine hydrochloride in 3.0 g deionized water. The solution was prepared by placing in a 10 x 35 mm Petri dish. Crystallization was performed by slow evaporation at room temperature in an open container (a method commonly used in the field of crystallography). Ambient humidity was maintained below 30% with a laboratory dehumidifier. The treated betaine hydrochloride was irradiated with a 670 nm continuous wave diode laser modulated at 10 MHz and phase conjugated to a primary beam output of 2.7 mW to 1.35 mW. A 5 mm diameter beam was passed through the center of the liquid meniscus of the treatment solution throughout the crystallization process. A control untreated betaine hydrochloride was also prepared under the same conditions except that it was not irradiated with a sparse constructive nodal laser system.

  The crystal formation quality of the control and laser treated betaine hydrochloride is shown in FIGS. 5A and 5B. The crystallographic term for the overall geometric shape of the formed crystal is crystal habit. 5A and 5B, the left control crystal has a crystal habit that is significantly different from the right treated crystal.

  The enlarged side view of 5A shows a significant difference between the control and laser treated betaine hydrochloride. The control crystal has countless inclusion defects, surface irregularities and a fairly shallow depth. In contrast, the treated crystals exhibit a high degree of uniformity, defect-free, smooth surface, and depth from front to back. The front view of 5B shows the wavy irregular surface of the control crystal and a rough outline. In contrast, the laser treatment crystal on the right shows a much smoother surface and smooth contour.

  These figures show the homogenization process. Betaine hydrochloride tends to have a skeletal twist and its shape in solution is not constant. Even after slow evaporation over several hours, the difference in shape interfered with the regular alignment in the crystal lattice, leaving gaps and irregularities in the crystal. Since a slightly different shape was added to the crystal growth zone, the growth surface was deformed and the crystal became irregular.

  In contrast, betaine hydrochloride grown under the influence of laser homogenization achieved self-similarity that resulted in the formation of highly organized crystals without global defects. The slight heating of the medium that can occur with the application of low power lasers, if any, would cause the organization to be compromised, but was suppressed by the sparse constructive node effect.

  It is important to note that the production of control crystals by slow evaporation is a very gentle process compared to the normal industrial drying mode in which bulk quantities of product are dried. Typically, fairly high temperatures up to the thermal decomposition threshold of the compound are used.

  Such aggressive conditions will substantially increase the broader and more extreme deformation tendency of the molecular structure through random thermal motion and more intense dehydration. Sparse constructive node laser irradiation can be applied during the dry powder (as in Examples 1, 3 and 4) or during the dehydration process to homogenize the molecular shape and thereby improve bioavailability.

  X-ray crystallography was performed using a SMART device manufactured by Siemens. Figures 5C and 5D show the intermolecular hydrogen bonding of the control and laser treated betaine hydrochloride, respectively. FIG. 5C shows four intermolecular hydrogen bonds per molecule of untreated betaine hydrochloride. In contrast, FIG. 5D shows only three intermolecular hydrogen bonds for each molecule of treated betaine hydrochloride. This is a soft feature of crystallography, but a decrease in the number of hydrogen bonds can increase the solubility; if the substrate is rapidly dissolved in solution, it can promote faster absorption of the molecule.

  FIG. 5E shows the crystal solution of the control and laser treated betaine hydrochloride viewed through X-ray crystallography. A crystallographic solution is a process that measures the exact localization of all atoms in a molecule to be analyzed using an X-ray diffraction pattern.

  In the two diagrams, the dotted line shows the structure of the control untreated betaine hydrochloride and the solid line shows the structure of the laser treated betaine hydrochloride. The upper diagram shows a depiction of the skeletal model and the lower diagram shows a depiction of the ball and stick model. In both diagrams, the treated betaine hydrochloride shows the expected effect of molecular flattening and elongation. In particular, carbon-nitrogen bonds (of methyl groups), carbon-oxygen bonds, and, to a lesser extent, carbon-hydrogen bond planarization and elongation are observed.

  Homogenization and molecular flattening and elongation can increase the efficiency of the enzyme mild reaction by at least three basic mechanisms, thereby improving bioavailability. Increasing the homogenization of the substrate is similar to increasing the substrate concentration for an enzyme isoform suitable for the substrate. In any enzyme mild reaction, increasing substrate concentration will proportionally increase reaction rate and product production.

  Second, the flattest shape is likely to have a homogeneous minimum energy state. In this configuration, the bond strength is the lowest, but the field strength is the highest. This is a very reactive state because the substrate behaves as a whole molecule.

  Moreover, the high self-similarity from molecule to molecule promotes enzyme binding. This is because the enzyme binds much faster (even to molecules that are only slightly different in size) to the same molecule that has just been released. This means that the rate at which the reactants are fed is directly proportional to the self-similarity of the molecules in the reactants (a constant multiple). Thus, the cells produce more product as the reactant molecules are similar to each other in terms of dimensional shape and water distribution. Molecules exposed to sparse nodal illumination are generally highly similar in terms of water distribution and location, tend to have maximally flat low energy shapes and high electrical and magnetic moments, and are very self-similar in all dimensions. I will.

  Betaine hydrochloride crystals made from exposed and unexposed betaine hydrochloride showed this effect markedly. This is because small individual differences build up and become large macroscopic differences visible in the grown crystal. Self-similarity also reduces the need for extensive production of enzymes to moderate a given reaction compared to when cells are presented with various forms of reactants that crystallize very heterogeneously. To do. Increasing the binding energy and dimensional similarity between molecules generally favors the production of any product in an enzyme mild reaction, thereby increasing bioavailability.

  The process of a cell that produces a product can be viewed as a manufacturing process in which cells take up raw materials from one end and aim to produce a specific product at the other end. The concept of a nutritional supplement at a basic level is to provide the raw materials needed for a given product. If this is not the case, a prior reaction of extracting (nutrients) from available food is required. The principle of nutritional supplements is therefore to reduce the complexity of the reaction for a given product and thus reduce the energy and time required for its production.

  Increasing the homogeneity of the nutritional supplement simply enhances the same principle that further reduces the complexity of the reaction and increases the speed and efficiency to produce the desired product. Thus, bioavailability is enhanced over non-homogenized nutrients. Similarly, drugs that are intended to increase the desired product in the body through an enzyme mild reaction (such as when producing dopamine from L-dopa) are also untreated if laser homogenized. Will show potential for increased bioavailability and reduced side effects.

  In addition, agents designed to increase receptor activity (eg, the beta blocker propranolol) may exhibit similar shape-grading effects of biological activity. It is well known that receptor-ligand matching is highly shape dependent. Homogenizing to a highly self-similar flattened shape with high electric and magnetic field moments will act as if the ligand concentration has increased for the desired receptor-ligand effect. This may allow both low doses to obtain similar clinical benefits, as well as reduced adverse effects at similar dose levels.

Example 8
Clinical effects of laser-treated betaine to reduce homocysteine and improve clinical symptoms Randomized prospective placebo comparisons to measure the effects of laser-treated betaine plus metabolic cofactors on methylated metabolism and clinical symptoms A blinded study was conducted. Methylation metabolism is the transfer of a simple organic chemical group methyl group (CH ₃ ) consisting of carbon atoms bonded to three hydrogen atoms.

  Methyl group transfer, also known as single carbon transfer, is one of the most fundamental and important chemical transfers in cell biology. Transfer of methyl groups is a number of processes that change the production of DNA, repair and maintenance of cell membranes, synthesis and balance of neurotransmitters in the central nervous system, and proteins, lipids, and sugars to their biologically useful configurations. Involved in other processes.

  Methylation metabolism is also closely involved in DNA regulation and biological timing mechanisms. Given the broad importance of methyl transfer metabolism, therapeutic agents that enhance methyl metabolism would be expected to have significant potential for improving overall metabolic balance and related clinical conditions.

  A key indicator of the integrity of methyl metabolism in the body is homocysteine concentration. Elevated homocysteine in serum indicates an impairment of one or more major methyl metabolic pathways. Elevated homocysteine is clinically relevant. According to published epidemiological data, the following charts:

As shown in the figure, when the homocysteine concentration exceeds 6.3, the relative risk of cardiovascular disease increases exponentially.
Moreover, elevated homocysteine is also associated with increased risk of stroke, Alzheimer's disease, pre-eclampsia, congenital neural tube defects, fetal death, human hostility, and malignancy. In homocystinuria, a metabolic disorder in which homocysteine can be as high as several hundred, accelerated aging, neurological disease, and atherosclerosis are very aggressive at an early age.

  Homocysteine is produced in the body as a metabolic byproduct of the amino acid methionine. There are three major pathways that the body uses to remove homocysteine, and if it works effectively, it can prevent the homocysteine concentration from rising to a dangerous level.

  The first pathway is a transsulfuration pathway that uses vitamin B6 (pyridoxine) and zinc to detoxify homocysteine to the amino acid cysteine. Methionine and cysteine are the main sulfur-containing amino acids, and methionine can be converted to cysteine via homocysteine if the pathway is not impaired. Some people cannot phosphorylate pyridoxine to its activated state. Such persons must be administered pyridoxal-5'-phosphate to overcome metabolic inhibition.

  The second homocysteine detoxification pathway is a pathway that re-methylates homocysteine back to methionine using vitamin B12 and folic acid. B12 and folate deficiency is well known to cause neurological, mental and hematological disorders. Impaired methyltransferase metabolism impairs the synthesis of DNA, neurotransmitters, and myelin and can lead to anemia, dementia, psychosis, and peripheral nerve disease. In particular, folate deficiency is associated with an increased risk of colon and cervical cancer and congenital anomalies of the central nervous system. Genetic defects in this pathway are common in some populations, for example, 38% of French Canadians are heterozygous for a lack of activity in the methyltetrahydrofolate reductase enzyme. Proactive support of a complete methyl metabolic pathway can significantly reduce the health consequences of such inborn metabolic disorders.

  A third pathway for homocysteine removal, and perhaps most clinically, is the use of betaine as a methyl group donor. Through the enzyme betaine-homocysteine methyltransferase found in the liver and kidney, the methyl group of betaine is transferred to homocysteine, which is converted to the essential amino acid methionine. Betaine itself is a derivative of the amino acid glycine (3 amino hydrogen atoms are replaced by 3 methyl groups). Thus, betaine is a methyl group-rich methyl group donor, also known as N, N, N-trimethylglycine, or simply TMG.

  In a double-blind clinical trial conducted by Morrison et al. In 1953, the effect of administration of methyl group transfer factor on subjects who had just recovered from myocardial infarction was examined. Treated subjects received 9 g daily high dose betaine + vitamin B12, liver extract, and creatine precursor. One year later, subjects who received placebo had a mortality rate of 25%, whereas the treatment group had no deaths. This was a very significant reduction in mortality in the treatment group.

  Humans with homocystinuria, the most extreme scenario of impaired methyl metabolism, also show reduced homocysteine levels with vitamins B6, B12 and folic acid, but often do not show significant improvement in clinical status. In contrast, the addition of high doses of betaine (typically 6-9 g daily) reverses whitening hair (to its original color), improves cardiovascular conditions and even reverses neuropathy Also accompanies. Women with homocystinuria can also conceive as well as normal pregnancy and full-term delivery if betaine is added to the regimen.

Betaine intake is also associated with reduced body fat, increased muscle mass, and increased exercise capacity. Betaine also plays a role in regulating intracellular osmotic pressure, particularly in the kidney.
In particular, methionine production in the liver is one of the most important processes of methyl metabolism. The methionine molecule combines with the energy molecule ATP (adenosine triphosphate) through the action of the SAMe synthetase enzyme to form an S-adenosyl-methionine (SAMe) molecule. SAMe thus formed is a powerful methyl group donor in cell metabolism and is involved in several tens of methyl group transfer reactions.

  In particular, all DNA methyltransferases, enzymes that regulate DNA transcription, senescence and repair through DNA methylation, exclusively use SAMe as the DNA methyl group donor. In addition, SAMe also donates methyl groups to proteins, lipids, and carbohydrates, changing them to biologically active configurations. In particular, membrane lipids require methylation for optimal fluidity and receptor function.

From a neurological point of view, SAMe provides a methyl group for the synthesis and equilibrium of neurotransmitters, in particular the synthesis of serotonin, and the production of the insulating myelin sheath of the nerve.
Several therapeutic benefits have been reported in double-blind clinical trials with ingested SAMe. An antidepressant effect comparable to tricyclic antidepressants was seen at a daily dose of 1600 mg. For tricyclic drugs, the antidepressant effect of SAMe was seen within one week. This is in contrast to the tricyclic drug therapy, which usually takes 4-6 weeks to achieve clinical benefit. Moreover, anti-cholinergic and cardiovascular adverse effects are frequently observed with tricyclic drugs, whereas the use of SAMe is essentially free of side effects.

  Other reported clinical benefits of SAMe include osteoarthritis pain reduction and increased function, fibromyalgia symptoms, and improved cardiovascular health. The use of SAMe has also been reported to protect the liver from toxins and promote liver repair and even cirrhosis repair. The latter effect appears to be related to SAMe enhancing methylation in the liver, an important pathway of detoxification.

  Once SAMe donates its methyl group, it then becomes S-adenosyl-homocysteine (SAH). When the adenosyl group is released, homocysteine is the resulting byproduct. FIG. 6A shows a general overview of the methyl group transfer pathway. While administration of SAMe has clinical benefits, it also has the potential disadvantage of increasing homocysteine loading.

  A more ideal way to optimize methyl metabolism would be to increase endogenous SAMe production while reducing homocysteine levels, as long as SAMe is sufficiently elevated. Betaine administration is a strong candidate for lowering homocysteine while raising SAMe. This is because animal studies have shown that administration of betaine can increase hepatic SAMe concentration up to 4-fold. Consistent with betaine's achievement in increasing hepatic SAMe concentrations, administration of betaine has also been shown to protect the liver from the harmful effects of toxins, and in particular, the liver from alcohol-induced toxicity.

  To support this role of betaine, a case study of a young woman with severe homocystinuria and major neuropathy showed a marked resolution of neurological deficits that were not obtained with vitamin alone when betaine was added. . In addition, betaine was added to the regimen and her cerebrospinal fluid SAMe concentration rose from an almost undetectable concentration to a normal concentration, along with clinical improvement.

  As a pilot study, blood SAMe concentrations in female subjects with osteoarthritis were measured during ingestion of SAMe and then during ingestion of betaine formulations. Subjects took 800 mg of SAMe per day, which provided moderate relief of knee pain. Within 3 months of taking this amount of SAMe, her blood SAMe concentration was 4.9 (the normal range for this experiment was 4.2-8.2). At this point, SAMe was discontinued and a methylated formulation containing 1 g of laser treated betaine + laser treated metabolic cofactor was started. Betaine and metabolic cofactors were in the same ratio as the double-blind clinical trial formulations described below.

  One month later, her blood SAMe concentration rose to 6.2 and her right knee pain almost completely resolved. Therefore, administration of a precursor of SAMe rather than SAMe itself resulted in a significantly higher blood SAMe concentration and a greater clinical response. In particular, the double effect of SAMe elevation and homocysteine suppression is expected to preserve and improve the DNA methylation status. This is because SAMe is the exclusive methyl group donor for DNA methylation.

  Homocysteine elevation has been found to be the most reliable marker of DNA methylation disorders other than direct measurement of DNA methylation status. Elevated homocysteine is also associated with accelerated shortening of vascular endothelial cell telomeres. Telomeres are the ends of chromosomes and tend to shorten with each cell division. If telomeres become too short, cells tend to lose their ability to replicate. Thus, elevated homocysteine is associated with two basic DNA aging mechanisms. Therefore, the reduction of homocysteine is expected to have a significant effect in supporting life extension.

  The pattern of DNA methylation at birth is crucial for the functional integrity of each cell type. The methyl group is on a specific cytosine residue and differentiates the DNA expression of each cell type by blocking transcription of genes that are not suitable for production in that cell line. The methyl group on a particular cytosine residue thus acts as a control block, preventing the expression of genes inappropriate for that cell type. This mechanism prevents, for example, brain cells from making muscle proteins and prevents muscle cells from making proteins that are restricted to brain cells only. Thus, every cell line has a particular pattern of which residues in the genome undergo cytosine methylation.

  Thus, this methylation pattern serves as a type of fingerprint that differentiates one cell line from another cell line through blockade of a transcriptional gene product that is not appropriate for that cell line. Cytosine methylation is a central regulatory process that determines which about 100,000 genes of the human genome will be expressed in a particular cell line.

  The gradual loss of methyl groups from DNA is one of the most important timing mechanisms of aging and DNA degradation in cells. At birth, depending on the cell type, cytosine methylation levels range from 2-6% of cytosine residues. The highest level of DNA methylation in humans and other mammals is typically found in the thymus, with a cytosine methylation level of 6%. As methyl groups are gradually lost from DNA, transcription integrity and DNA regulation are reduced. DNA may initiate transcription of genes inappropriate for that particular cell line. Oncogenes may lose their methylation-inhibiting effect and be at risk of activation. That is, changes occur that can increase the likelihood of tumor formation. Cytochemistry associated with impaired methylation in turn increases the risk of DNA strand breaks and mutations.

  Loss of 20% methyl groups from birth, at least in part due to DNA changes associated with demethylation, is associated with a marked increase in the risk of certain malignancies, especially colon and cervical cancer . Focusing on one variable, folic acid, it has been shown that humans with high folic acid concentrations have an approximately 50% lower risk of colon or cervical cancer than those with low concentrations.

  In the case of humans and other mammalian species, degenerative death is likely to occur at a DNA demethylation level of 40%. At this DNA demethylation level, the integrity of information is greatly impaired when it spreads throughout the tissue, so living organisms are no longer supported. Thus, any factor that slows, stops or reverses the loss of methyl groups from DNA will tend to slow, stop or reverse the aging process at the DNA level.

  A 50% DNA demethylation level throughout the body generally does not support survival, but loss of this level can occur in selected tissues in some situations. In particular, 50% DNA demethylation has been selectively reported in lymphocyte populations in autoimmune diseases, systemic lupus erythematosus and rheumatoid arthritis.

  The extreme loss of DNA information integrity in these immunoregulatory cells forms the basis of dysfunction, resulting in an immune system that recognizes self-antigens as heterologous antigens and initiates a destructive inflammatory process against them. Bring. Various anti-inflammatory drugs serve primarily to reduce terminal inflammatory effects rather than addressing underlying information and DNA dysregulation. In contrast, correction of methylation abnormalities in diseased immune cells can help to correct autoimmune conditions at the level of information dysregulation.

  Increased homocysteine associated with accelerated DNA demethylation and telomere shortening is a marker of accelerated aging process at the DNA level. Any program that seeks to achieve a life-prolonging effect must be directed to DNA methylation, SAMe generation, and complete homocysteine concentration.

  The pathologic action of homocysteine is not limited to promoting DNA demethylation. Homocysteine is also an important factor in the increased pathogenicity of cholesterol in the pathogenesis of vascular diseases. Homocysteine and thiolactone bind to LDL cholesterol and promote LDL oxidation.

  Animal studies have shown that administration of high doses of non-oxidized cholesterol has little effect on blood vessels, but the addition of oxidized cholesterol, even in trace amounts, can lead to rampage of atherosclerosis. Has been. The effect of homocysteine inducing LDL cholesterol oxidation can greatly increase atherogenesis of LDL cholesterol even at concentrations considered in the normal range.

  In addition, high homocysteine increases the binding of lipoproteins and fibrin. High homocysteine also tends to increase the tendency of soluble clotting factors to clot. Both of these factors increase the likelihood of clot formation and vascular occlusion, particularly in vulnerable vascular plaque areas. This can lead to heart attacks, strokes, or peripheral tissue gangrene.

  Studies on vascular tone have shown that the higher the homocysteine concentration is above physiological normal values, the greater the inhibition of nitric oxide production from vascular endothelium. Since nitric oxide dilates blood vessels, inhibition of nitric oxide impairs the ability of affected blood vessels to dilate in response to the need for greater blood flow. Antagonism of nitric oxide production increases the likelihood of vasospasm and increases the likelihood that the tissue will suffer ischemia, the reduction in blood flow and oxygenation necessary to support tissue survival.

  High homocysteine may promote atherosclerosis through these multiple mechanisms, impair vasodilation necessary for proper blood flow, or increase the likelihood of clot formation. For these reasons, homocysteine can be a very large risk factor for juvenile heart attacks (under 55 years) and subsequent high cholesterol, as well as stroke and peripheral vascular disease. High homocysteine has been shown to increase the relative risk of juvenile heart attack up to 40-fold (the relative risk of high cholesterol is only about 4-fold).

  From a malignant tumor perspective, homocysteine has been found to accumulate in malignant cells and interfere with DNA and protein chemistry. Administration of methylation-enhancing nutrients to smokers with precancerous bronchial cytology markedly regressed and returned to normal, but bronchial cytology in the placebo control group showed no improvement . Furthermore, administration of methylation enhancing factors appears to improve the clinical course of lymphoma.

  Lowering homocysteine levels and improving methyl metabolism can have a wide range of benefits, including anti-aging effects, reduced cardiovascular risk, and reduced risk and course of malignancy. SAMe elevation is also associated with relief from depression and osteoarthritis symptoms, improved fibromyalgia symptom profile, and improved heart and liver health and function.

  A randomized, placebo-controlled, double-blind prospective clinical trial was conducted to assess the effects of laser-treated betaine + laser-treated cofactor on homocysteine levels and other clinical and metabolic profiles. The comprehensive protocol for human clinical trials followed the Western Institutional Review Board (WIRB), Olympia, Washington. This protocol has been approved to follow generally accepted guidelines for human clinical trials.

  Subjects were recruited from local newspapers from the Seattle and Olympia areas of Washington. Forty subjects over 40 years old were selected as participants. In selecting a test group that is expected to have at least a moderate increase in homocysteine concentration, the lowest age of 40 years is selected as the homocysteine concentration tends to increase with age, and The effect was investigated.

  Test formulations that were designed and laser treated for enhanced methylation metabolism contained the following components in the stated proportions. That is, betaine (trimethylglycine) 2000 mg, choline bitartrate 750 mg, inositol 500 mg, inositol hexanicotinate 375 mg (niacin, vitamin B3 non-flushing type, 80 wt% niacin, or 300 mg niacin is provided), magnesium Amino acid chelate 18.42% 162.9 mg (providing 30 mg magnesium), cyanocobalamin 1% 100 mg (providing 1 mg vitamin B12), pyridoxine hydrochloride 25 mg (vitamin B6), zinc chelate 20.17% 24.8 mg ( 5 mg zinc is provided as an amino acid chelate), 37 mg calcium chloride, 27 mg magnesium stearate, 5 mg pyridoxal-5′-phosphate (phosphorylated biphenyl) Min B6), and folic acid 1.6mg. These components were measured by weight and mixed with a commercially available mixing apparatus so that a uniform density and distribution were obtained. The total weight of the preparation balanced with 2 g of betaine was 4.008 g, and 668 mg of each was packed into six 00 size gelatin caps.

  The test methylation-enhanced formulation was treated with sparse constructive node laser irradiation with a main laser wavelength of 670 nm. Two GaAs diode lasers were used with the primary outputs of 4.6 mV and 3.0 mV being phase canceled to 2.3 mV and 1.5 mV, respectively. These lasers were further electronically modulated at 10 MHz. The test preparation was placed in a transparent plastic container at a rate of 2 kg per container. Each container was treated with double laser irradiation for 12 minutes per container while rotating with a gyroscope. What is the average laser dose? It was 044 kg / min / mV.

  Subjects were randomized into treatment or placebo groups after participating in the study. Baseline homocysteine levels were stratified by concentration from high to low, and two-thirds of subjects in each range were randomized and actively treated with laser-treated methylated products, one-third A placebo was administered.

  All subjects who received treatment were informed about the protocol of the study and signed an informed consent document before the start of the study. All subjects took 18 cobalt blue opaque gelatin capsules that made it difficult to tell if they were receiving a placebo or active formulation. During the first month of the study, the treatment group received 2 g of laser homogenized betaine plus a corresponding amount of lasered cofactor daily. The weight of the subtracted portion of the capsule was filled with maltodextrin 580, a hypoglycemic carbohydrate polymer of glucose that does not appear to significantly affect methyl metabolism.

  In the second month of the study, the treatment group received 4 g of laser homogenized betaine plus a corresponding amount of lasered cofactor daily. The deductible weight of the capsule was filled with maltodextrin. In the third month of the study, the treatment group received 6 g of laser homogenized betaine + a corresponding amount of lasered cofactor daily. This amount completely filled the capsule, so no additional maltodextrin was necessary. All capsules ingested by the placebo group throughout the study were filled with maltodextrin alone.

  All subjects completed a daily questionnaire that indicated the number of capsules they would take each day. In the daily questionnaire, subjects also recorded the food and drink they consumed, the amount of exercise, the presence and amount of smoking, and their overall mood, energy, and sleep quality and time. In addition, a space was provided to record any symptomatic benefits, side effects or general comments.

  Intake and study completion studies were also conducted immediately before and at the end of the study. In addition to the general diet, exercise, health and smoking questions asked above, these studies included the presence of any known medical problems, medication use, dietary supplement intake, and any alcohol or caffeine intake. Also asked about.

At baseline and every week of the study, all subjects completed a clinical evaluation questionnaire known as SCL-90-R. SCL-90-R manufactured by National Computer Systems (NCS) is an abbreviation for Symptom Checklist 90-revised version. The SCL-90-R is a 90-question survey used in "a clinical trial that helps measure changes in symptoms such as depression and anxiety" which is widely used and statistically very effective. It is a concise multidimensional self-report list that screens for psychopathological symptoms and provides an indication of general mental distress. The NCS provides a scoring template that shows a subject's percentile rank for each symptom score tested to compare the subject with the general population. The test scales measured include anxiety, depression, delusions, obsession, somatization (perception of physical dysfunction), and hostility, and a global severity index (combined for all symptoms). Index measured together).
, Etc. At baseline and at the end of each study period, subjects were sent to the clinical laboratory of St. Peters Hospital, Olympia, Washington, for hemoptysis. Regularly measured blood tests include a complete blood count and leukocyte fraction and a chemical panel containing platelets, glucose, electrolytes, blood urea nitrogen (BUN), creatinine, liver enzymes, and triglycerides, total cholesterol, LDL cholesterol, and HDL It was a lipid panel containing cholesterol. The homocysteine concentration was also removed. In addition, blood samples were centrifuged and fractionated into red blood cells, white blood cells, and plasma components, which were then frozen and used for professional tests performed in an independent laboratory, ie, red blood cell SAMe and DNA methylation level tests. Samples were collected and shipped according to established laboratory protocols.

  For all fields measured, a maximum of 10 subjects dropped out of any measurement. The main reasons for removing subjects from the data analysis were one or more blood test defaults or documentation deficiencies, medical or metabolic conditions that interfered with the analysis, or other administration reasons.

  Since this study achieved baseline and three different dose measurements, a statistical analysis of autoregression for multiple measurements was employed. Since this method uses each subject as their own control, a formal control group is not required for statistical analysis. The placebo control group was used in this study to rule out significant irregular variations in metabolic measurements tested primarily without the test formulation.

  The decrease in homocysteine concentration is statistically significant at all doses administered, with p <. 00001. The mean homocysteine concentration in the treatment group dropped from baseline 9.1 to 7.1 one month after administration of the test formulation with 2 g of laser homogenized betaine + laser treated cofactor. The second and third dose levels, i.e. 4 g and 6 g homogenized betaine + proportionally increased amounts of laser-treated cofactor in the treatment group, decreased by mean homocysteine values of 6.8 and 6.1, respectively. there were. 6.1 was the concentration that positioned the treatment group at the generally lowest cardiovascular risk level below the general population for homocysteine.

FIG. 6B shows a graph of the dose response curve. Statistical significance at each dose level is also noted.
The placebo control group started with a homocysteine concentration that was not statistically different from the treatment group. There was no significant reduction in homocysteine concentration during the 3-month study period. If anything, there was a small statistically insignificant increase in homocysteine concentration. The mean homocysteine value of the placebo control group during the 3 month test period is shown graphically in FIG. 6C.

  Since higher elevations of homocysteine are correspondingly associated with cardiovascular and other high risks, the subgroup of treated subjects starting with the highest homocysteine concentration was analyzed separately for dose-response effects.

  FIG. 6D shows a dose response curve for a laser treated test formulation for subjects with a baseline homocysteine value of 10 or greater. The mean reduction was statistically significant at all dose levels, with a 30% reduction from 13.2 to 9.3 for the lowest dose test formulation. At higher doses, the homocysteine concentration further decreased to 8.3 and 7.3 on average after 2 and 3 months, respectively. The highest proportional decrease was 15 for baseline homocysteine but dropped to 5 after 2 months of use of the test formulation, or about 70% for homocysteine. These results indicate that laser homogenized methylated formulations can be particularly helpful in regulating and reducing the highest risk increase of homocysteine.

  Use of the test formulation was also associated with a statistically significant reduction in the anxiety scale. FIG. 6E shows a linear dose response curve showing a greater decrease in anxiety as the dose of test formulation increases. In contrast, there was no significant reduction in the anxiety scale in the placebo group.

FIG. 6F shows a very significant decrease in the bodyization scale (physical distress, tingling and pain perception). In particular, a steep decrease was seen at the lowest dose level.
FIG. 6G shows a statistically significant decline in depression. This decline increases with higher dose levels. Since the test formulation is expected to increase the SAMe concentration, the results shown in FIGS. 6F and 6G will be the effect of reported direct use of SAMe, ie osteoarthritis or fibromyalgia It is consistent with the effect of reducing tingling and pain, and the effect of alleviating depression.

FIG. 6H shows a very statistically significant reduction in obsessive-compulsive symptoms at all dose levels.
FIG. 6I shows a significant linear decline in paranoia symptoms with increasing dose of the test formulation.
FIG. 6J shows a statistically significant reduction in hostility with the use of the laser homogenized test formulation. Recent studies have shown that high homocysteine and human hostility are correlated. This is one of the first therapeutic interventions that shows not only a reduction in homocysteine but also a corresponding reduction in measured hostility.

  FIG. 6K shows a general-measured dose response curve that comprehensively evaluated the overall severity index, ie, a measure of all symptoms and severity. This indicator shows a very statistically significant decline in the overall symptom profile at all dose levels, with the decline increasing with each dose, showing a significant relative response, especially at the lowest dose.

  Improving basic transmethylation biochemistry specifically includes cell membrane fluidity and function, neurotransmitter production and balance (especially serotonin), post-transcriptional modification of proteins, DNA synthesis and repair, endothelial vascular protection And at the level of many other facilitating pathways, it is expected to have broad benefits in cellular metabolism and function.

  Optimal use of laser homogenized methylated formulations can be adjusted based on the response to treatment of homocysteine concentration, SAMe concentration, DNA methylation assay, inflammatory markers, or changes in clinical status. In clinically good humans, it may be advisable to adjust the dosage of the formulation to maintain the homocysteine concentration associated with the lowest cardiovascular risk, ie, a cut-off value of 6.3 or less.

Example 9
A case of lupus improved by laser-treated methylated drug as a model for alleviating autoimmune disease pathology Autoimmune disease recognizes autoantigens as foreign and initiates an inflammatory attack of the immune system against the self tissue It is a state to do. Central to the disease process is an information abnormality in the immune system's ability to distinguish host tissue components from foreign or invasive antigens.

  The phenomenon repeatedly observed in the two most common autoimmune diseases, lupus and rheumatoid arthritis, is the high DNA demethylation of T cell lymphocytes. Although DNA demethylation of lymphocytes is a phenomenon secondary to the inflammatory response, the DNA demethylation process can also play a major role in the pathogenesis of the disease through dysregulation of the DNA control mechanism. Recent studies showing that clinical improvement of rheumatoid arthritis by methotrexate treatment is associated with increased DNA methylation supports the hypothesis that DNA demethylation is the etiology of the disease.

  Degenerative death usually occurs when body tissues undergo an overall 40% DNA demethylation. In rheumatoid arthritis and lupus, demethylation of up to 50% of T cell lymphocytes is observed, suggesting the promotion of these immunoregulatory and effector cell selective degenerative processes. Aggressive treatments that re-methylate DNA can help mitigate and correct information abnormalities at the underlying DNA level, rather than merely suppressing the inflammatory response associated with impaired immune regulation.

As an example of a patient, a 59-year-old white woman has had recurrent lupus for several years. At the time of participating in the methylated formulation trial of Example 6, she had experienced a recurrence of severe illness for several months.
Her illness was characterized by painful blistering and ulcerative lesions that were extremely sensitive to the limbs, which made it difficult to walk without severe pain and open the cabinet doors. The skin was pale, extremely fatigued in a chronic low energy state, and suffered from severe hair loss. The sedimentation rate, which is a marker of systemic inflammation, was elevated to 99, while the normal level was 0-30. Although treated with plaquenil alone, symptoms were rarely alleviated. She refused to use corticosteroids. This is because there were severe treatment side effects at the time of previous recurrence.

  The subjects were randomized to a placebo control group and did not see any improvement in status for 3 months. In the second phase of the study, she was put 6 g of laser treated betaine + cofactor in a daily high dose methylated formulation group. Within 1-2 weeks of starting the active formulation she began to notice clinical improvement.

  At the end of the three-month phase II, she reported 90% disappearance of limb lesions and a marked improvement in fatigue and fatigue. At this point her settling rate had fallen to 58. She continued with the same amount of plakenil throughout the study, and the only change in treatment was the addition of active methylated formulation during the second phase of the study for 3 months.

  The subject continued on a low dose laser treated methylated formulation reduced to 1-2 g laser treated betaine + cofactor for an additional 5 months. During this period she had a complete remission of all clinical symptoms. At the end of the fifth month of low-dose treatment, her sedimentation rate had dropped to a very low normal value of 1. This was the lowest level she has ever recorded.

  Other clinical markers also showed a marked improvement in her underlying disease lupus. The C-reactive protein before treatment increased to 3.4 (normal 0 to 1.5), but decreased to normal 1.1 at the end of the treatment period.

  Pre-treatment C3 and C4 complement concentrations have decreased to 84 (normal 94-192) and 11.5 (13.0-52.0), respectively, and active inflammatory processes are consuming complement factors It showed that. By the third month of the high-dose methylated formulation, her concentration returned to normal and C3 and C4 were 98 and 13.2, respectively. In other words, it showed a decrease in autoimmune inflammation. Anti-double stranded DNA antibodies are specific markers for SLE. The titer that had risen to 1:40 dilution before treatment (normal <1:10 dilution) had essentially dropped to the normal value of 1:10 dilution by the end of the first month of use of the high dose formulation. .

  She obtained complete disappearance of limb lesions and complete resolution of all other clinical features. Her energy returned to a high level for the first time in several years. Her pallor has disappeared and her hair has re-grown.

  She stopped using methylated preparations at this point and felt clinically good for 7 months. However, the repeated sedimentation rate 7 months after discontinuation of the formulation showed an increase to 103. Within a few weeks of increasing sedimentation rates, early onset of finger pain and hand skin lesions began. Within a few weeks of resuming high-dose laser-treated methylated formulations, early relapse symptoms were completely resolved. By continuing to use the formulation, the sedimentation rate returned to normal again.

  Her experience is consistent with numerous studies of methylation chemistry that show that biochemical markers tend to return quickly to pre-treatment levels after discontinuation of methylation enhancer delivery. In general, consistent use over a long period is recommended for best results.

  Systemic lupus erythematosus is a prime example of a wide range of autoimmune conditions that make an immune attack against self-antigens. Aggressive remethylation with laser-treated methylated products considers all forms of autoimmune disease, especially diseases like rheumatoid arthritis and lupus known to be characterized by reduced lymphocyte methylation Is an appropriate treatment. Such treatment has a very high treatment index and may be useful for the treatment of underlying DNA dysregulation rather than merely suppressing symptoms due to inflammatory processes.

Example 10
Inactivation of prions using laser acoustic resonance and the possibility of reshaping other proteins Prions are a class of unique proteinaceous infectious agents, especially known for causing slowly progressive neurodegenerative diseases ing. Prions differ from other types of infectious agents in that they do not require DNA or RNA effector mechanisms to cause pathological changes. It has been observed that prions pass through microfilters that are too small to pass even the smallest viruses or bacteria. The prion is also resistant to sterilization at temperatures normally effective to remove pathogenic microorganisms. Due to deceptive biological strategies unrelated to nucleic acids, methods for treating these destructive disease states have not yet been developed.

  The human syndrome most closely associated with prion infection is Creutzfeldt-Jakob disease. Although rare, Creutzfeldt-Jakob disease is the most common spongiform encephalopathy in humans characterized by vacuolar changes and astrocyte proliferation in brain tissue. Disease transmission has been reported to be due to contaminated stereotactic electrode implants for growth hormone injection, corneal transplantation, and epilepsy treatment prepared from pooled human pituitary extracts. The incubation period is typically in the range of 15 to 31 months. The average disease duration is approximately 6 months from progressive dementia, myoclonus, and motor dysfunction to death.

As defined by Prusser, prions are “small proteinaceous infectious particles that are resistant to inactivation by methods that modify nucleic acids”. Perhaps the most unusual feature of this type of disease is that the pathogenic protein appears to be encoded by the genome of the host cell. The gene for human prion protein (PrP) is mapped to chromosome 20. The normal gene product PrP ^c appears to have the same amino acid sequence as the pathological protein PrP ^sc . Differences in three-dimensional folding convert normal mutants of membrane sialoglycoprotein into abnormal isoforms. This aggregates into nodules of pathological proteins that are visible by electron microscopy. Prion aggregates can be responsible for amyloid plaques and fibrils found in brain tissue of this group of diseases.

  Chaperonins are a class of effector proteins that help shape peptide sequences into their biologically active three-dimensional conformation. Impaired chaperonin activity in prion diseases can be otherwise responsible for abnormal folding and aggregation of normal peptide sequences.

  A chaperonin-like effect can be provided by applying the “shock and ringing” of sparse constructive nodes and simultaneously aligning and shaping molecules with their EM field waves that are relatively large compared to the molecular size. Sparse constructive nodes and EM field patterns can mimic the shaping process in chaperonin pockets and help guide the three-dimensional folding of peptide sequences. Thus, the ability to alter the shape of individual amino acids of sparse constructive node irradiation can be extended to amino acid chains, helping to desirable polypeptide folding patterns.

  In order to determine whether laser acoustic resonance could favor normal conformation rather than the pathological conformation of PrP, we decided to do both forms of acoustic spectral analysis. If the preferred vs. unsuitable acoustic spectrum is different, in principle it may be possible to help form the desired shape by applying sparse constructive node laser radiation modulated at the preferred spectral frequency. is there. Even so, it is possible to make the total energy required to switch from one configuration to the other sufficiently higher than the energy achievable by resonance before the other attenuation losses become dominant.

  A cost effective method for determining the acoustic resonance spectrum applied to a complex molecule would be to create a single point acoustic emitter in solution using sonoluminescence by supersaturated carbon dioxide bubble nucleation. A major example of sonoluminescence is the use of ultrasound to compress small bubbles to an infinitesimal size and suddenly and dramatically increase the temperature. This sometimes leads to thousands of degrees of temperature rise in small spaces.

  In some systems, this temperature spike (often accompanied by light) can be used to directly drive chemical reactions, but in this context bubble nucleation can be used to measure the acoustic absorption spectrum of molecules in solution. Used to create single point acoustic emitters.

  For example, when carbon dioxide is dissolved in water using a “soda stream” and a broadband hydrophone made of PVDF (polyvinylidene fluoride) is placed in the water, the acoustic spectrum of pure water is measured. When the selected test molecule is dissolved in water, the absorption spectrum changes. This differential absorption spectrum shows the frequency of the main vibration mode of the test molecule. Furthermore, the narrow absorption line indicates the homogeneity of the compound in solution.

  In a typical use case, we choose the maximum absorption line and adjust the laser modulation to that frequency. Such a main resonance frequency can be delivered to the molecule very efficiently. This provides an additional level of molecular shape control in addition to the general "shock and ring" effect using photon absorption and re-emission Dirac-like acoustic spikes.

In a simple experiment of homogenization, a dry powder (or solution) of a compound is divided into two batches. One batch is irradiated with the modulation frequency chosen from prior CO ₂ nucleation absorption spectrum analysis. This powder is then added to the CO ₂ solution and the control powder is added to another CO ₂ solution. Next, the absorption spectra of each of the two solutions are measured. Once homogenization occurs, the irradiated sample will show a narrower absorption spectrum than the control sample.

  Simple compounds such as betaine show relatively few absorption lines, but there are hundreds of compounds such as fibronectin or glucoamylase. Each line selected for irradiation is expected to narrow after irradiation.

In the case of prions, normal and pathological prion configurations are dissolved in separate CO ₂ solutions and the absorption spectra of these solutions are measured. Next, when the absorption peak seen in the normal prion is regenerated with the pathological prion solution as compared with the pathological prion, it can be brought close to normal resonance and arrangement. The frequency is applied as a modulation of the sparse constructive node beam of laser acoustic resonance.

  Conversely, regenerating the pathological prion absorption peak with a pathological solution can heat enough local resonances to disrupt the overall structure. Such intense local heating can simply denature the three-dimensional conformation, or can break the covalent bond if targeted to a weak bond. The main laser wavelength is shifted to the violet-ultraviolet end of the electromagnetic spectrum if resonance modification is intended. On the other hand, the infrared-red end of the spectrum is more suitable as a reconstruction strategy.

  The ability to convert a pathological prion to a normal configuration or to modify the structure has the potential to serve as a fast, low energy sterilization method for tissue or implantable devices. This energy can also be applied as a direct in vivo treatment, because sparse constructive nodes have a greater penetration depth into the tissue compared to normal conventional laser EM irradiation. Removal of pathological prions from clinical samples, tissues, and larger laboratory instruments as well as clinical safety can also be achieved.

  Further development has applicability to livestock and livestock industries. Prion disease in animals that cause spongiform encephalopathy is particularly well recognized as scrapie in sheep and goats and as mad cow disease in cattle. Applications include the treatment or prevention of this otherwise untreatable disease or the sterilization of infectious or infectious tissues or contaminated devices.

From the viewpoint of general application, the process of using the luminescent CO ₂ nucleation absorption spectrum analysis _{(sonoluminescent CO 2 nucleation absorption spectral analysis} ) may provide resonance modulation frequency to further enhance the homogenization intended effect. Other spectroscopic methods can be used, but the advantages of this proposed preferred mode are its ease and cost effectiveness.

  Modulating the sparse constructive node of the laser irradiation with the resonance spectral peak can cause more specific structural changes in addition to the general homogenization and planarization effects. This may be particularly important to enhance the desired effects of drugs, particularly drugs targeted to receptor effects. This can further improve receptor shape adaptation, increase the desired treatment effect at a given dose, and reduce non-specific dose related and dose independent adverse effects.

  In order to more specifically target such a wide range of dietary supplement and pharmaceutical effects, further in vitro, animal and clinical trials depending on the desired effect will be required. The first candidate for such an effect would be to alter the action of drugs that function in the receptor pathway of the phenolic neurotransmitters dopamine, epinephrine, and norepinephrine. Skeletal twisting and global planarization and the ability to change the shape of the phenol (hydroxylated benzene) ring-containing molecule can enhance the desired function and reduce the often serious side effects.

  In fact, all receptor-ligand and enzyme-substrate mediated systems are very shape dependent. The ability to change and homogenize the shape of the ligand or substrate concentrates the shape-changing effect to increase or decrease the reactivity of the system as desired. Thus, by altering a wide range of nutrients, drugs, and other bioactive agents, the intended biological or physiological effect can be enhanced.

  Special resonances using high frequency blue-violet to ultraviolet main laser systems may be found to denature specific pathogens. A wide range of pathogens may be inactivated using sparse intensifying laser irradiation modulation.

  Special resonant systems greatly increase the temperature of selected chemical bonds, making them more reactive. Some covalent bonds are susceptible to cleavage, resulting in reactive fragments of special shape and structure. This can be used to create a reaction sequence that is thermodynamically unfavorable for increasing the yield of structures that are otherwise difficult to produce or create new beneficial compounds.

  Thus, the use of sparse constructive node resonant laser irradiation reshapes prions to make them no longer pathogenic; enhances or even mimics endogenous enzymes, receptors, and signaling systems; And it has the potential to change components of a wide range of infectious agents or toxins to reduce their pathogenicity or toxicity.

Example 11
Clinical Effects of Laser-treated L-Arginine, which Reduces Blood Pressure and Cholesterol Concentration Subjects from the double-blind study of Example 6 were invited to a Western IRB approved Phase 2 study after completion of the Phase 1 study. Subjects in the placebo group were invited to participate in a dose response study of the laser treated L-arginine formulation. Subjects in the active treatment group were invited to add a dose response study of the laser treated L-arginine formulation while continuing the high dose methylated formulation.

  Each size 00 capsule of the laser treated L-arginine formulation was formulated to provide 500 mg of homogenized L-arginine. Furthermore, each capsule contained a laser processing component having the following composition. Inositol hexanicotinate 25 mg (80% molar ratio niacin or 20 mg niacin), pyridoxine (vitamin B6) 2.5 mg, magnesium amino acid chelate 18.42% 54.3 mg (provided 10 mg magnesium), zinc amino acid Chelate 20.17% 4.1 mg (providing 0.833 mg of zinc), and selenomethionine 0.5% 2.33 mg (providing 11.67 μg of selenium chelated to methionine), and 11 mg of calcium pantothenate (vitamin B5) .

  Laser homogenization of arginine + supplemental vitamins and mineral cofactors was performed as follows. 2 kg of the dry powder of this formulation was weighed into a transparent plastic container and placed in a gyroscope device that rotated the product through three shafts. Two 670 nm diode lasers with primary outputs of 4.6 mV and 3.0 mV were changed to laser irradiation of sparse constructive nodes of 2.3 mV and 1.5 mV, respectively. The beam was further electronically amplitude modulated at 10 MHz. The average laser dose during a 12 minute treatment time per container is. It was 044 kg / min / mW.

  Subjects who were in the treatment group in the Phase 1 study continued on the dose of 6 g laser treated betaine plus laser homogenized cofactor, the highest daily dose treated methylated formulation from Phase 1. In the first month, subjects took 9 capsules of the laser-treated arginine formulation daily. This is the amount that provides 4.5 g of activated arginine plus a proportion of the processing cofactor. In the second month, the daily dose was increased to 18 capsules, a base of 9 g of laser treated arginine. In the third month, the daily dose was increased daily to 27 capsules, ie 13.5 g (since the digestive tract accepted).

  The placebo group in the Phase 1 study was switched to take only the laser-treated arginine formulation. During the second phase, 1, 2 and 3 months, the base dose of arginine is 4.5g, 9g, and 13.5g, respectively, with the same proportion of laser-treated cofactor, and the comparison group also took the treated methylated preparation did.

  Three subjects refused to take activated arginine complex. The reason for this is that arginine is known to have a tendency to recur herpes simplex virus outbreaks, or studies suggest that it should be used with caution in people with autoimmune diseases. It was either. One of these participants was a subject with active lupus. The process is described in Example 7. All subjects in this group received the highest dose of laser-treated methylated formulation studied, ie 6 g of treated betaine + proportional cofactor.

  The subject continued to fill out the daily questionnaire described in Example 6. In particular, the daily capsule intake of each capsule was recorded and subjective benefits or side effects were also reported. A weekly SCL-90 questionnaire was also conducted. At the end of the test, the subject completed the graduation questionnaire and test summary.

  At baseline and monthly, patients also received and analyzed the following blood tests: That is, examination of triglycerides and total, LDL, and HDL cholesterol concentrations, and red blood cells, white blood cells, and plasma at an independent laboratory for advanced research. In addition, at baseline and monthly, subjects also received blood pressure measurements at the time of blood collection. Approved informed consent documents were provided by Western IRB for Phase II trials. After reviewing and signing these informed consent documents, subjects began a second three-month study phase. During the second phase, subjects who took the laser homogenized L-arginine formulation showed a statistically significant reduction in total cholesterol, LDL cholesterol, and total to HDL cholesterol ratio. It took 2-3 months of use to show a significant decrease in these measurements. In addition, systolic and diastolic blood pressure also showed a statistically significant decrease, which also required use for 2-3 months to achieve a significant level. The triglyceride concentration also decreased from an average of 140 to 118, but this decrease did not achieve statistical significance.

  In contrast to the Phase 1 study, which steadily ingested the recommended dose of capsules, the intake was very variable in the Phase 2 study. Instead of a dose-response curve, the results show a long-term cumulative effect of bulk dose intake for the entire group.

  Based on the total capsule intake obtained from the daily report, the intake range of the laser-treated L-arginine formulation for the first month was 105-410 capsules. The average intake was 210 capsules, or about 7.0 capsules per day. The intake range for the second month was 126-513 capsules, and the average intake was 386 capsules, or about 12.9 capsules per day. The intake range for the third month was 27-756 capsules, and the average intake was 436 capsules, or about 14.5 capsules per day. Therefore, the average daily intake of laser homogenized L-arginine during the first, second, and third months was 3.5 g, 6.5 g, and 7.3 g, respectively.

  One-way repeated measures analysis of variance was used to analyze the effect of laser homogenized L-arginine formulations on total cholesterol concentration over time. The analysis was limited to 29 subjects whose baseline total cholesterol exceeded 180. According to the multivariate test, a significant cholesterol-lowering effect, Wilkes' lambda =. 77, F (2,26) = 3.813, p =. 035 is shown. This effect took two months to become apparent.

  By baseline to the end of the second month, 18 of 29 or 62% of treated subjects had reduced total cholesterol. Of those who showed a reduction in total cholesterol, 61% showed a reduction of 10% or more and 18% showed a reduction of 20% or more. The 32% maximum individual total cholesterol reduction was a reduction from baseline 213 to a post-treatment concentration of 146.

  One-way repeated analysis of variance was used to test the effect of laser homogenized L-arginine formulations on LDL cholesterol over time. According to the multivariate test, significant LDL cholesterol lowering effect, Wilkes' lambda =. 655, F (3, 20), p =. 034 is shown. Furthermore, paired t-test analysis revealed that the most significant LDL cholesterol drop occurred after the third month of treatment. The average baseline concentration increased to 140, but decreased to 128 after the third month of treatment. This is a clinically important level of decline.

  Of the 26 subjects whose baseline cholesterol exceeded 180, 61% showed a reduction in LDL cholesterol after 3 months of treatment with laser homogenized L-arginine. Among those who showed a decrease, 75% were a decrease of 10% or more and 25% were a decrease of 20% or more. The largest single drop was 66%, down from a very high concentration of 223 to a normal concentration of 75.

  To assess the relative effects on HDL cholesterol, a one-way repeated measures analysis of variance was calculated for the dependent variable total to HDL cholesterol ratio. Multivariate analysis of variance shows a significant effect on this ratio decline over time, Wilkes' lambda =. 691, F (3, 21), p =. 048 is shown. The average baseline ratio 4.1 dropped to 3.8 after 3 months of treatment. 63% of subjects showed a decrease in this ratio, though a 7% decrease.

  A one-way repeated measures analysis of variance was calculated for the long-term systolic blood pressure of the dependent variable. The independent variable was the treatment formulation. There was a statistically significant decrease in systolic blood pressure over time. Wilkes' Lambda 715, F (3,26) = 3.447, p =. 03: A significant linear effect was also observed. F (1,28) = 6.522, p =. 016.

  Mean systolic blood pressure 131 for the entire group decreased to 126 after 3 months of treatment with the laser homogenized L-arginine formulation. The paired t-test comparing baseline and 3 months of treatment is p =. It was statistically significant at 004. In a subgroup of subjects with systolic hypertension greater than or equal to 140 mmHg, 9 out of 10 or 90% showed a decrease in systolic blood pressure after treatment with the test formulation for 3 months. The decrease is p =. 033 was statistically significant. The pre-treatment values for this group ranged from 140-208 mmHg but decreased to 123-160 mmHg after treatment. The decrease range of the systolic blood pressure of the subjects who showed a decrease was 2 to 48 mmHg, and the average decrease was 19.4 mmHg.

  A one-way repeated measures analysis of variance was calculated for the dependent variable diastolic blood pressure. The independent variable was the intake of the laser homogenized L-arginine formulation taken over 3 months. Univariate analysis of variance showed a significant reduction in diastolic blood pressure. F (3,26) = 4.014, p =. 01. A significant linear effect on diastolic blood pressure reduction was also observed. F (1,28) = 7.236, p =. 012. With a paired t-test, a statistically significant decrease in diastolic blood pressure was observed for 2 months from baseline (p = 0.043) and 3 months from baseline (p = 0.19). )

  Baseline mean diastolic blood pressure 82 gradually decreased to 81, 78, and 76 at 1, 2, and 3 months, respectively. There were only 5 subjects with diastolic hypertension above 90 mmHg, but 80% showed a reduction in diastolic blood pressure, the pre-treatment range 90-128 mmHg dropped to 60-99 mmHg after 3 months of treatment . In subjects with diastolic hypertension and a decrease in diastolic blood pressure, the range of decrease was 9-40 mmHg and the average decrease was 25.8 mmHg diastolic.

  None of the subjects with low normal systolic or diastolic blood pressure had blood pressure dropped to low blood pressure levels. It was found that the laser homogenized L-arginine formulation does not have this problem at all, although it is a serious potential side effect commonly seen with other antihypertensive drugs.

  With high doses of laser treated L-arginine, some subjects experienced gastrointestinal side effects, particularly diarrhea. The literature shows that ingestion of untreated L-arginine typically up to 15 g per day does not cause loose stool. Some subjects were able to tolerate 13.5 g of laser-treated L-arginine when taken in divided doses, but there are sometimes subjects who develop loose stool even at as little as 4.5 g, and the efficacy of L-arginine is generally It suggests that it is increasing. In either case, reducing the intake below the individual's GI symptom threshold level resulted in resolution of symptoms.

  In addition, male subjects reported that taking the laser-treated L-arginine formulation improved rather than impairing erectile function. In contrast to many hypertensive drugs that can cause impotence, L-arginine supplementation can often increase sexual function, and even a significant percentage of men tested improved impotence. This is due to the effect that nitric oxide production induced by L-arginine stimulates increased cyclic GMP in genital tissue, resulting in vasodilation where specific signals cause an erectile response.

  The use of laser homogenized L-arginine can thus improve the total to HDL cholesterol ratio while effectively reducing total and LDL cholesterol. It also safely and effectively reduces systolic and diastolic blood pressure. Side effects are relatively few and mild and are usually resolved easily by dose reduction.

  Thus, the present invention can improve the bioavailability of nutrients, drugs, and other bioactive compounds in the mammalian body by treating the compound with a laser to alter the average structure of the compound. . Improving bioavailability increases the availability of functional groups used in biological processes in the body by increasing compound absorption, reducing inflammation or other negative reactions to compounds Can be achieved. Further, since the treatment can be performed on compounds in dry or solution form, it is possible for those skilled in the art to modify a wide range of nutrients, drugs and other compounds to enhance bioavailability in humans and other mammals. It will be relatively easy.

  Accordingly, disclosed herein is an improved method for administering dietary amino acids, drugs, and other bioactive substances. While various materials are disclosed in this disclosure, those skilled in the art will recognize that myriad other materials can be modified within the teachings of the present invention without departing from the scope and spirit of the invention. . The appended claims are intended to cover such variations.

FIG. 5 shows an X-ray powder diffraction (XRPD) pattern of a control simvastatin sample Sim1A. FIG. 6 shows an XRPD pattern of a laser-treated simvastatin sample Sim1B showing an increase in crystallinity. FIG. 6 shows an XRPD pattern of a laser-treated simvastatin sample Sim2A showing low intensity reflection indicating amorphous content. FIG. 4 shows an XRPD pattern of a laser-treated simvastatin sample Sim2B showing very low intensity reflection with even higher amorphous content. FIG. 2 shows front and side micrographs of control untreated L-arginine hydrochloride monohydrate crystals. It is a figure which shows the microscope picture of the front and side surface of a crystal | crystallization of laser processing anhydrous L-arginine hydrochloride. FIG. 5 shows the results of X-ray crystallography of laser treatment or modified L-arginine hydrochloride. FIG. 2 shows a quantitative EEG (QEEG) test of baseline alpha electroencephalogram coherence. It is a figure which shows the QEEG test of alpha electroencephalogram coherence 1 hour after an untreated amino acid intake. It is a figure which shows the QEEG test of alpha electroencephalogram coherence 1 hour after laser treatment or modified amino acid intake. FIG. 3 is a side micrograph of a control betaine hydrochloride and laser treated or modified betaine hydrochloride crystals. It is a figure which shows the front micrograph of the crystal | crystallization of a control betaine hydrochloride and a laser processing or modification betaine hydrochloride. It is a figure which shows the result of the X ray crystallography of the intermolecular hydrogen bond of the control betaine hydrochloride. It is a figure which shows the result of the X-ray crystallography of the intermolecular hydrogen bond of a laser processing or modification betaine hydrochloride. It is a figure which shows the result of the X-ray crystallography of the molecular structure of a control betaine hydrochloride (dotted line) and a laser treatment or a modified betaine hydrochloride (solid line), the upper figure shows a skeleton model and the lower figure shows a model of a ball and a rod. It is a figure which shows the diagram of a methyl group transfer metabolic pathway. It is a graph which shows the fall of the homocysteine density | concentration after a process with a modified betaine. It is a graph which shows a control group. FIG. 6 is a graph showing the reduction of homocysteine as a function of treatment dose in subject subgroups with moderately high baseline cysteine concentrations (≧ 10). FIG. 6 is a graph showing a decrease in anxiety as a function of treatment volume. FIG. Fig. 6 is a graph showing the decline in somatization as a function of treatment volume. 6 is a graph showing the reduction of obsessive-compulsive symptoms as a function of treatment dose. Figure 6 is a graph showing depression depression as a function of treatment volume. FIG. 6 is a graph showing paranoia decline as a function of treatment dose. FIG. 6 is a graph showing hostility decline as a function of treatment volume. FIG. 5 is a graph showing a decrease in overall severity index as a function of treatment dose.

Claims (69)

Producing a modified trimethylglycine and cofactor by subjecting the trimethylglycine and cofactor to laser radiation; and ingesting an effective amount of the modified trimethylglycine and cofactor;
How to treat anxiety.   The method of treating anxiety according to claim 1, wherein the method comprises consuming at least 2 g of modified trimethylglycine and a cofactor per day.   The method of treating anxiety according to claim 1, wherein the method comprises consuming at least 4 g of modified trimethylglycine and cofactors per day.   2. The method of treating anxiety according to claim 1, wherein the method comprises consuming at least 6 g of modified trimethylglycine and cofactors per day.   The method comprises forming the modified trimethylglycine and cofactor by exposure to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the trimethylglycine and cofactor; The anxiety treatment method according to claim 1, wherein is constructed in a polarization and wave pattern. Producing a modified trimethylglycine and cofactor by subjecting the trimethylglycine and cofactor to laser radiation; and ingesting an effective amount of the modified trimethylglycine and cofactor;
How to treat depression.   7. The method of treating depression according to claim 6, wherein the method comprises consuming at least 2 g of modified trimethylglycine and a cofactor per day.   7. The method of treating depression according to claim 6, wherein the method comprises consuming at least 4 g of modified trimethylglycine and a cofactor per day.   7. The method of treating depression according to claim 6, wherein the method comprises consuming at least 6 g of modified trimethylglycine and a cofactor per day.   The method comprises forming the modified trimethylglycine and cofactor by exposure to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the trimethylglycine and cofactor; 7. The method of treating depression according to claim 6, wherein the is constructed in a polarization and wave pattern. Producing a modified trimethylglycine and cofactor by subjecting the trimethylglycine and cofactor to laser radiation; and ingesting an effective amount of the modified trimethylglycine and cofactor;
How to treat obsessive-compulsive symptoms.   12. The method of treating obsessive-compulsive symptoms of claim 11, wherein the method comprises consuming at least 2 g of modified trimethylglycine and a cofactor per day.   12. The method of treating obsessive-compulsive symptoms of claim 11, wherein the method comprises consuming at least 4 g of modified trimethylglycine and cofactors per day.   12. The method of treating obsessive-compulsive symptoms of claim 11, wherein the method comprises consuming at least 6 g of modified trimethylglycine and cofactors per day.   The method comprises forming the modified trimethylglycine and cofactor by exposure to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the trimethylglycine and cofactor; The method of treating obsessive-compulsive symptoms according to claim 11, wherein is constructed in a polarization and wave pattern. Producing a modified trimethylglycine and cofactor by subjecting the trimethylglycine and cofactor to laser radiation; and ingesting an effective amount of the modified trimethylglycine;
How to treat paranoia.   17. The method of treating paranoia according to claim 16, wherein the method comprises consuming at least 2 g of modified trimethylglycine and a cofactor per day.   17. The method of treating paranoia according to claim 16, wherein the method comprises consuming at least 4 g of modified trimethylglycine and a cofactor per day.   17. The method of treating paranoia according to claim 16, wherein the method comprises consuming at least 6 g of modified trimethylglycine and a cofactor per day.   The method comprises forming the modified trimethylglycine and cofactor by exposure to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the trimethylglycine and cofactor; The paranoia treatment method according to claim 16, wherein is constructed in a polarization and wave pattern. Producing a modified trimethylglycine and cofactor by subjecting the trimethylglycine and cofactor to laser radiation; and ingesting an effective amount of the modified trimethylglycine and cofactor;
How to deal with hostility.   22. The hostile treatment method of claim 21, wherein the method comprises consuming at least 2 g of modified trimethylglycine and cofactors per day.   24. The hostile treatment method of claim 21, wherein the method comprises consuming at least 4 g of modified trimethylglycine and cofactors per day.   22. The hostile treatment method of claim 21, wherein the method comprises consuming at least 6 g of modified trimethylglycine and cofactors per day.   The method comprises forming the modified trimethylglycine and cofactor by exposure to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the trimethylglycine and cofactor; The hostile treatment method of claim 21, wherein the is constructed in a polarization and wave pattern. Producing a modified trimethylglycine and cofactor by subjecting the trimethylglycine and cofactor to laser radiation; and ingesting an effective amount of the modified trimethylglycine and cofactor;
How to treat physical pain, tingling and pain perception.   27. A method of treating physical pain, tingling and pain perception according to claim 26, wherein the method comprises consuming at least 2 g of modified trimethylglycine and cofactors per day.   27. A method of treating physical pain, tingling and pain perception according to claim 26, wherein the method comprises consuming at least 4 g of modified trimethylglycine and cofactors per day.   27. The method of treating physical pain, tingling and pain perception according to claim 26, wherein the method comprises consuming at least 6 g of modified trimethylglycine and cofactors per day.   The method comprises forming the modified trimethylglycine and cofactor by exposure to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the trimethylglycine and cofactor; 27. A method of treating physical distress, tingling and pain perception according to claim 26, wherein is constructed in a polarization and wave pattern. Producing a modified betaine and cofactor by subjecting said betaine and cofactor to laser radiation; and ingesting an effective amount of said modified betaine and cofactor;
Methods for treating autoimmune abnormalities.   The method maintains or adjusts at least 6 g of laser treated betaine + cofactor per day for 2-3 months of induction, and then based on clinical or biochemical response, 1-2 g of said 32. A method of treating an autoimmune disorder according to claim 31 comprising consuming a maintenance dose of laser treated betaine + cofactor.   The method includes forming the modified betaine + cofactor by exposure to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the betaine + cofactor, wherein the laser radiation is polarized 32. The method for treating an autoimmune abnormality according to claim 31, wherein the autoimmune disorder is constructed in a wave pattern. A method for modifying an amino acid to be beneficial for the supply of systemic and tissue amino acids in inflammation, autoimmunity, and allergic conditions to reduce an immune response to said amino acid,
Said method comprising producing a modified amino acid by subjecting said amino acid to laser radiation; and ingesting an effective amount of said modified amino acid.   The method comprises forming the modified amino acid by exposure to laser radiation that is amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the amino acid, the laser radiation being constructed into a polarized and wave pattern. 35. A method for modifying an amino acid according to claim 34 to reduce an immune response to said amino acid. A method for reducing inflammation through modification of amino acids to reduce production of inflammatory cytokines responsive to said amino acids, comprising:
Said method comprising producing a modified amino acid by subjecting said amino acid to laser radiation; and ingesting an effective amount of said modified amino acid.   The method comprises forming the modified amino acid by exposure to laser radiation that is amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the amino acid, the laser radiation being constructed into a polarized and wave pattern. 37. A method for reducing inflammation through modification of an amino acid according to claim 36 to reduce production of inflammatory cytokines responsive to the amino acid. A method for improving the quality of crystal formation through increasing homogeneity of unit cell elements or reducing defects in crystal lattices, or both,
Selecting the molecular species to be crystallized; and subjecting said molecular species to laser radiation during the crystallization step.   The method includes subjecting a selected molecular species to laser radiation amplitude-modulated at a resonance frequency of one or more acoustic vibration frequencies of the molecular species during the crystallization step, wherein the laser radiation is polarized and 39. A method for improving the quality of crystal formation through increasing homogeneity of unit cell elements and / or reducing crystal defects as constructed in a wave pattern. A method for improving the quality of an already solidified crystal through homogenization of unit cell elements and / or liberation of trapped water in the crystal lattice,
Selecting said crystal form to be homogenized and / or dried; and subjecting said crystal form to laser radiation.   The method includes subjecting the selected crystal form to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the molecular species of the selected crystal form, the laser radiation being polarized 41. A method for improving the quality of crystals already solidified through homogenization and / or drying of unit cell elements according to claim 40, which is constructed in a wave pattern. Dissolving simvastatin in a solvent and subjecting said simvastatin to laser radiation during the crystallization process;
Method for producing highly crystalline and homogeneous simvastatin.   The method comprises dissolving the simvastatin in a solvent and subjecting the simvastatin to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the simvastatin, wherein the laser radiation is polarized and waved 43. A method of producing highly crystalline and homogeneous simvastatin according to claim 42, which is constructed in a pattern. Dissolving simvastatin in a solvent and subjecting said simvastatin to laser radiation during the crystallization process;
A method for producing amorphous simvastatin.   The method comprises dissolving the simvastatin in ethanol or another solvent, and subjecting the simvastatin to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the simvastatin. 45. The method of producing amorphous simvastatin according to claim 44, wherein is constructed in a polarization and wave pattern. Selecting an enzyme, substrate, or ligand to be modified; and subjecting the enzyme, substrate, or ligand to laser radiation to modify its structure;
A method for modifying the activity of an enzyme, substrate, or ligand.   The method selects an enzyme, substrate, or ligand to be modified; and laser emission wherein the enzyme, substrate, or ligand is amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the enzyme, substrate, or ligand. 49. The method for modifying the activity of an enzyme, substrate, or ligand according to claim 46, wherein said laser radiation is constructed in a polarization and wave pattern. A method for increasing the depth and range of photodynamic therapy treatment effects by increasing the penetration depth of laser electromagnetic signals and energy into the tissue, comprising:
The method identifies a condition in the tissue that can respond to photodynamic therapy; and determines the appropriate photodynamic compound, photoactivated laser wavelength, and laser radiation dose to use in the treatment of the condition; and Administering the photodynamic compound to allow sufficient time for the compound to accumulate in the tissue to be treated; and applying a sufficient dose of sparse constructive node laser radiation to the tissue to be treated by the external beam Applying endoscopically, intraarterially, or as required by other routes, wherein the laser radiation is amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the photodynamic compound, A method as described above, wherein the laser radiation is constructed in a polarization and wave pattern. Modified molecules by homogenizing, flattening, and reducing skeletal torsional distortions of aromatic amino acids and L-dopa, and any other dopaminergic, catecholaminergic, or serotonergic precursors, compounds, or drugs A method for enhancing the bioavailability of a structure, comprising:
Selecting a dopaminergic, catecholaminergic, or serotonergic precursor, compound, or drug to be modified; and laser emitting said dopaminergic, catecholaminergic, or serotonergic precursor, compound, or drug And said method comprising:   Selecting a dopaminergic, catecholaminergic, or serotonergic precursor, compound or agent to be modified; and said dopaminergic, catecholaminergic, or serotonergic precursor, compound, or agent 50 with a laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the precursor, compound or agent, wherein the laser radiation is constructed into a polarization and wave pattern. Homogenizing, flattening, and reducing skeletal twist distortion of aromatic amino acids and any other dopaminergic, catecholaminergic, or serotonergic precursors, compounds, or drugs described in A method for enhancing bioavailability. A method for homogenizing, flattening, and reducing skeletal torsional distortions of nutrients, drugs, or other bioactive substances to enhance the bioavailability of the modifier,
Selecting the nutrient, drug, or other bioactive substance to be modified; and treating the nutrient, drug, or other bioactive substance with laser radiation.   The method selects a nutrient, drug, or other bioactive substance to be modified; and the nutrient, drug, or other bioactive substance is one or more of the nutrient, drug, or other bioactive substance. 52. A nutrient, agent, or other biologically active substance according to claim 51, comprising treating with laser radiation amplitude modulated at a resonance frequency of the acoustic vibration frequency of said laser radiation, wherein said laser radiation is constructed in a polarization and wave pattern A method for enhancing the bioavailability of modifiers by homogenizing, flattening, and reducing the distortion of skeletal torsion. A method for increasing the bioavailability of a nucleobase, nucleoside or deoxynucleoside, or nucleotide or deoxynucleotide monophosphate, diphosphate, or triphosphate, comprising:
Selecting a nucleobase, nucleoside or deoxynucleoside, or nucleotide or deoxynucleotide monophosphate, diphosphate, or triphosphate; and subjecting the selected substance to laser radiation to modify its structure; Said method.   Said method selects a nucleobase, nucleoside or deoxynucleoside, or nucleotide or deoxynucleotide monophosphate, diphosphate or triphosphate to be modified; and said nucleobase, nucleoside or deoxynucleoside, or nucleotide or deoxy Nucleotide monophosphate, diphosphate, or triphosphate having one or more acoustic vibration frequencies of the nucleobase, nucleoside or deoxynucleoside, or nucleotide or deoxynucleotide monophosphate, diphosphate, or triphosphate. 54. A nucleobase, nucleoside or deoxynucleoside, or nucleotide or deo according to claim 53, comprising irradiating laser radiation amplitude modulated at a resonance frequency, wherein the laser radiation is constructed in a polarized and wave pattern. Shi nucleotide monophosphate, diphosphate, or three methods for increasing the bioavailability of phosphate. A method for increasing the biological activity of a high energy phosphate of nucleotides or deoxynucleotides, comprising:
Selecting said nucleotide or deoxynucleotide to be modified; said method comprising subjecting said nucleotide or deoxynucleotide to laser radiation.   A laser wherein the method selects a nucleotide or deoxynucleotide to be modified; and the nucleotide or deoxynucleotide is amplitude modulated at a resonant frequency of one or more acoustic vibration frequencies of the high energy phosphate of the nucleotide or deoxynucleotide. 56. A method for increasing the biological activity of a high energy phosphate of nucleotides or deoxynucleotides according to claim 55, comprising irradiating the radiation, wherein the laser radiation is constructed in a polarized and wave pattern. 129. The method of claim 128, which increases the bioavailability of a nucleobase, nucleoside or deoxynucleoside, or nucleotide or deoxynucleotide monophosphate, diphosphate, or triphosphate, whether not modified by laser treatment. There,
Making a solution of said nucleobase, nucleoside, or nucleotide monophosphate, diphosphate, or triphosphate at a concentration of at least 10 times the plasma concentration; and said solution is a nucleic acid element as occurs in the intestinal mucosa Applying said to the oral cavity or other non-intestinal mucosa for at least 30 seconds for direct transmucosal absorption in order to overcome the extensive degradation of. A method for enhancing or altering the production or purification of selected stereoisomers or epimers of a bioactive substance, comprising:
Selecting a stereoisomer to enhance or alter; and subjecting the stereoisomer or epimer to rotationally polarized laser light amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of the stereoisomer or epimer. And the laser radiation is constructed in a polarization and wave pattern. A method of reducing prion or other pathogenic proteins into other forms to reduce their pathogenicity,
Selecting a prion or other pathogenic protein that reshapes; and subjecting said prion or other pathogenic protein to laser radiation.   The method selects a prion or other pathogenic protein that reshapes; and selects the prion or other pathogenic protein at a resonance frequency of one or more acoustic vibration frequencies of the prion or other pathogenic protein. 60. The prion or other pathogenic protein according to claim 59 is reshaped into their pathogenicity, comprising irradiating the amplitude modulated laser radiation, wherein the laser radiation is constructed in a polarization and wave pattern How to lower. The method selects a prion or other pathogenic protein that reshapes; and the peak absorption frequency of the prion or other pathogenic protein and their non-pathogenic counterparts is determined by sonoluminescence by CO ₂ nucleation. Determined using absorption spectral analysis or other spectroscopy or mathematical modeling; and said prion or other pathogenic protein is a normal protein, pathogenic protein, or a differential absorption pattern between normal and pathogenic counterpart proteins. Subjecting the laser radiation to amplitude modulation at one or more peak absorption frequencies to reshape the prion or other pathogenic protein to reduce their pathogenicity, wherein the laser radiation is polarized and 61. A prion or other pathogenic tamper according to claim 60 constructed in a wave pattern. How to reduce their pathogenic reshaping the quality in another form. A method of reducing the pathogenicity of a pathogenic substance or an infectious pathogen by remodeling it into another form,
Selecting the one or more components of a pathogenic substance or infectious pathogen that reshapes; and subjecting the pathogenic substance or one or more components of the infectious pathogen to laser radiation.   The method selects one or more components of a pathogenic substance or infectious pathogen that reshapes; and one or more components of the pathogenic substance or infectious pathogen, the pathogenic substance or the infection 63. Applying laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of one or more components of a sexual pathogen, wherein the laser radiation is constructed in a polarization and wave pattern. The method of reducing the pathogenicity of the pathogenic substances or the components of infectious pathogens by changing them into another form. The method selects one or more components of a pathogenic substance or infectious pathogen that reshapes; and the peak absorption frequency of the pathogenic substance or one or more components of the infectious pathogen is expressed as a CO ₂ nucleus. Sonoluminescence absorption spectrum analysis by production or other spectroscopic methods or mathematical modeling; and one or more components of the pathogenic substance or the infectious pathogen are determined as the pathogenic substance or the infectious pathogen 64. The pathogenic agent or infection of claim 63, comprising: irradiating laser radiation that is amplitude modulated with one or more peak absorption frequencies of one or more components of the laser radiation, wherein the laser radiation is constructed in a polarization and wave pattern A method of reducing the virulence of reproductive pathogens by remodeling them into different forms. Selectively activate specific regions of selected molecules to increase production of desired products in chemical reactions, create new reaction sequences to obtain products, or special molecular shapes, properties, and activities A method for producing a new product production comprising:
Selecting the one or more molecular species to be modified; and subjecting said molecular species to laser radiation.   Said method comprising: selecting one or more molecular species to be modified; and subjecting said molecular species to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of said molecular species; 66. The laser radiation is constructed in a polarization and wave pattern to selectively activate specific regions of selected molecules of claim 65 to obtain a product that increases production of a desired product in a chemical reaction To produce a new reaction sequence for the production of a new product having a particular molecular shape, properties and activity. The method selects one or more molecular species to be modified; and the peak absorption frequency of a specific region of the selected molecular species to be modified is determined by sonoluminescence absorption spectroscopy by CO ₂ nucleation, other spectroscopy Using a method or through mathematical modeling; and subjecting the molecular species to laser radiation amplitude modulated at one or more peak absorption frequencies of the molecular species, wherein the laser radiation is polarized and waved 68. A novel reaction sequence to obtain a product that selectively activates a particular region of the selected molecule of claim 66 that is constructed in a pattern to increase production of the desired product in a chemical reaction. A method of creating or producing a new product with special molecular shape, properties, and activity. A method of selectively activating a molecular species or a specific region of a molecular species to produce a signal for qualitative or quantitative detection or analysis comprising:
Selecting and activating a specific molecular species or region of molecular species by resonance; and subjecting said molecular species to laser radiation amplitude modulated at a resonance frequency of one or more acoustic vibration frequencies of said molecular species The method as described above, wherein the laser radiation is constructed in a polarization and wave pattern. The method selects a specific molecular species or region of a molecular species and activates by resonance; and analyzes the peak absorption frequency of the specific molecular species or region of molecular species by sonoluminescence absorption spectrum by CO ₂ nucleation; Determining the molecular species using other spectroscopy or through mathematical modeling; and subjecting the molecular species to laser radiation amplitude modulated at one or more peak absorption frequencies of the molecular species, wherein the laser radiation comprises: 69. A method of selectively activating a molecular species or a specific region of a molecular species according to claim 68, constructed in a polarization and wave pattern, to produce a signal for qualitative or quantitative detection or analysis.

Images